Evaluation of SPN-812 (Viloxazine Extended-release Capsule) 200 and 400 mg Efficacy and Safety in Children With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
Phase: PHASE3
Conditions: ADHD
Sponsor: Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 1 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
TITLE PAGE 
Protocol Number: 
812P303 
Title: 
Evaluation of SPN-812 ER 200 and 400 mg Efficacy and Safety 
in Children with ADHD - A Double-Blind, Placebo-Controlled, 
Pivotal Trial 
Sponsor: 
Supernus Pharmaceuticals, Inc. 
  
Rockville, MD 20850 
United States 
 
 
IND number: 
108,864  
Investigational 
Medicinal Product: 
Viloxazine hydrochloride 
Indication: 
Attention Deficit Hyperactivity Disorder (ADHD)  
Contract Research 
Organization 
(CRO): 
 
 
 
CRO Medical 
Monitor 
 
 
 
 
 
  
 
Phase: 
3 
Protocol Version: 
4.0 
Date: 
17 September 2018 
Good Clinical 
Practice (GCP) 
Statement: 
This study is to be performed in full compliance with International 
Conference on Harmonization (ICH) Good Clinical Practices 
(GCP) and all applicable local regulations.  All required study 
documentation will be archived as required by regulatory 
authorities. 
 
 
 
 
 
 
 
 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 2 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
 
INVESTIGATOR’S SIGNATURE PAGE 
 
I, the undersigned, have read this protocol and agree to conduct this trial in accordance 
with all stipulations of the protocol and in accordance with ICH GCP and all applicable 
local guidelines, including the Declaration of Helsinki and all its accepted amendments to 
date. 
 
 
 
 
 
 
 
Principal Investigator’s Signature 
 
 
 
 
Date 
Print Name 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 4 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
CLINICAL PROTOCOL SYNOPSIS 
Name of Product:   
SPN-812 ER 
Name of Active Ingredient: 
Viloxazine Hydrochloride 
Protocol Number: 812P303 
Phase of Development:  3 
Full Title of Study:  Evaluation of SPN-812 ER 200 mg and 400 mg Efficacy and Safety in 
Children with ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial 
Investigator(s) / Center(s):  Approximately 25 US centers  
Objectives:  
Primary 
 
To evaluate the efficacy of SPN-812 extended-release (ER) compared to placebo as 
monotherapy for the treatment of ADHD in children (6 -11 years). 
 
Key Secondary 
 
To evaluate the effect of SPN-812 ER compared to placebo as assessed by: 
o 
Clinical Global Impression - Improvement (CGI-I) scale 
o 
Conners 3rd edition (Conners 3) – parent, composite T-score 
o 
Weiss Functional Impairment Rating Scale – Parent report (WFIRS-P) 
 
Additional Secondary 
 
To evaluate the effect of SPN-812 ER compared to placebo as assessed by: 
o 
50% Responder rate based on the ADHD-RS-5 Total score 
o 
Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) 
o 
ADHD-RS-5 Inattention and Hyperactivity/Impulsivity subscale scores 
o 
Conners 3 – Self, composite T-score (for ages 8-11 years) 
 
Safety 
 
To evaluate the safety and tolerability of SPN-812 ER in children with ADHD 
 
Exploratory 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 5 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
Study Design:  Randomized, double-blind, placebo-controlled, multicenter, 3-arm, parallel-
group, efficacy and safety pivotal study  
Number of Subjects:  Approximately 300 subjects (100 subjects per treatment) 
Criteria for Inclusion: 
Male and female subjects, 6-11 years of age, diagnosed with ADHD, parents/caregivers able to 
give consent and to follow the protocol requirements of the study. 
Criteria for Exclusion: 
History or presence of significant diseases, evidence of suicidality, allergy to viloxazine, or any 
other reason that could interfere with the subject’s participation in the study as determined by 
the Investigator. 
Treatment, Dose, and Mode of Administration: 
Study medication (SM): capsules containing either SPN-812 ER 100 mg or placebo  
Mode of administration: Each treatment will be administered once daily (QD) as a single oral 
dose. 
Dose: Subjects will be titrated up at 100 mg/week to the final randomized dose (1:1:1) as follows:  
Treatment A: Placebo  
Treatment B: SPN-812 ER 200 mg/day (2 x 100 mg SPN-812 ER) 
Treatment C: SPN-812 ER 400 mg/day (4 x 100 mg SPN-812 ER) 
Duration of Treatment and Study Duration:  
Screening window: within 28 days prior to Visit 2 (Baseline Visit) 
Titration period: 3 weeks  
Maintenance treatment period: 5 weeks  
Total subject duration on study: approximately 12 weeks (including up to 28 days of Screening) 
Total number of visits: 10  
Total duration of study: Approximately 12 months (9 months of enrollment). At the end of the 
study, eligible subjects will have the option to enroll in a separate, open-label extension study. 
Treatment Schedule: 
Screening (Visit 1):  After informed consent and informed assent (if applicable) is obtained, 
subjects will undergo initial screening evaluation including medical and psychiatric history, ECG, 
vital signs, physical examination, hematology and chemistry laboratory tests, and urine drug 
screen. A blood sample will also be drawn for PGx testing. ADHD diagnosis and severity will be 
confirmed and inclusion/exclusion criteria will be reviewed to confirm eligibility of the subject. 
Study Dose Treatment Phase (Visits 2 – 10): This phase will consist of three weeks of Titration 
followed by five weeks of Maintenance phase until end of study (EOS)/Visit 10. 
Baseline, Randomization, and Dispensation of SM (Visit 2):  Approximately 300 eligible 
subjects will be randomized.  Within 28 days of Screening Visit, eligible subjects will return for 
the Baseline Visit. After confirmation of eligibility (including a urine pregnancy test for Females 
of Childbearing Potential [FOCP]), subjects will be randomized and receive blinded study 
medication (SM).  
Study Dose Treatment: Titration (Visits 2-4): Subjects will return to the clinical site for weekly 
visits to undergo efficacy and safety evaluations and to pick up the next dosing card (Figure 1). 
Study Dose Treatment: Maintenance (Visits 5-10): Subjects will return to the clinical site for 
weekly visits to undergo efficacy and safety evaluations and to pick up the next dosing card 
(Figure 1). 
End of Study (Visit 10): Subjects will return for final evaluation (the same evaluation will be 
done if the subject terminated early). 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 6 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
Optional Substudy: Pharmacokinetic Sampling (Visits 3-10):  The following PK samples will be 
collected: pre-dose and 1, 2, 4, and 6 hours post-dose. 
Endpoints: 
Primary Endpoint: The primary endpoint in this study is the change from baseline (CFB) to EOS 
in the ADHD-RS-5 total score. 
Key Secondary Efficacy Endpoints: a) CGI-I, b) Conners 3 - Parent composite T-score, and c) 
WFIRS-P average score 
Additional Secondary Efficacy Endpoints: a) Proportion of responders with 50% improvement 
in ADHD-RS-5 Total score, b) PSI-4-SF, c) ADHD-RS-5 Inattention and 
Hyperactivity/Impulsivity subscale scores, and d) Conners 3 - Self composite T-score (for ages 
8-11 years) 
Exploratory Endpoints:  
 
 
 
 
Safety Assessments: Safety will be assessed using Adverse Events (AEs), clinical laboratory 
tests, vital signs, physical examinations, ECGs and the Columbia Suicide Severity Rating Scale 
(C-SSRS). 
Sample Size: 
Seventy-two subjects per treatment group in the Intent-to-Treat (ITT) population will yield 90% 
power at a significance level of 0.05 (two-sided) using a two-sample t-test with equal allocation 
to the treatment groups. This assumes an effect size of 0.547, observed in the comparison of 
SPN-812 200 mg and placebo in the SPN-812 Phase IIb study (based on the CFB to endpoint 
in the ADHD-RS-IV total score). A total of 300 subjects (100 subjects in each of the three 
treatment groups) will be randomized to account for an anticipated 27.9% of randomized subjects 
not completing the study. 
Analysis Populations: 
 
The Randomized population will include all enrolled subjects who had a baseline visit 
and are randomized via the IWRS. 
 
The ITT population for efficacy will include all randomized subjects who took at least one 
dose of study medication, and had a Baseline and at least one post-randomization 
ADHD-RS-5 assessment. Subjects will be analyzed according to the treatment to which 
they were randomized. 
 
The Per Protocol (PP) population consists of all subjects in the ITT population who 
completed all 10 visits with no missing ADHD-RS-5 assessments and no major protocol 
violations. Subjects will be analyzed according to the treatment they actually received. 
 
The Safety Population consists of all subjects randomized into the study who receive at 
least one dose of SM. Subjects will be analyzed according to the treatment they actually 
received. 
 
The PK population will include all subjects in the safety population with ≥1 PK sample 
that is not below the Lower Limit of Quantitation (LLOQ). 
Handling of Missing Data:  
With respect to the primary analysis, missing ADHD-RS-5 Total scores will be assumed to be 
missing at random (MAR) and will be handled using a Mixed Model for Repeated Measures 
(MMRM) method in SAS. The sensitivity analysis for the primary endpoint will be performed by 
assuming that missing ADHD-RS-5 Total Scores are missing not at random (MNAR). For 
analysis of secondary endpoints, missing values will be assumed as MAR.  
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 7 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
Statistical Methods: 
All tabulations of analysis results will include summaries for the following three treatments: SPN-
812 ER 400 mg, SPN-812 ER 200 mg, and placebo. 
Where appropriate, variables will be summarized descriptively (frequency count and percent for 
categorical variables, and number of subjects (n), mean, standard deviation (SD), median, 
minimum, and maximum for continuous variables).  
Categorical variables will be analyzed using categorical response methods such as Pearson’s 
Chi-square test. If expected frequencies are less than 5 in a given cell, then exact testing 
techniques will be used. 
Descriptive statistics will be presented for demographics, data from the clinical laboratory tests, 
vital signs, weight, ECGs, and C-SSRS.   
 
Efficacy Analyses 
Primary: The primary efficacy variable, change from baseline in ADHD-RS-5 Total Score to 
Week 8 (EOS), will be analyzed using a Mixed Model for Repeated Measures (MMRM), which 
assumes that missing data are missing at random (MAR). The model will include fixed effect 
terms for baseline ADHD-RS-5 Total Score, age group, treatment, visit, and treatment-by-visit 
interaction as independent variables. The model parameters will be estimated using restricted 
maximum likelihood method with unstructured variance-covariance matrix and Kenward-Roger 
approximation to estimate denominator degrees of freedom. In case there is a convergence 
problem in the MMRM model with the unstructured variance covariance matrix, the first 
(co)variance structure which does not have convergence problem will be used for the analysis 
from the following ordered list: 1) Toeplitz, 2) Autoregressive of order 1, and 3) Compound 
symmetry. 
The adjusted mean (LS Mean) of CFB to EOS for ADHD-RS-5 Total Score for each treatment 
group (Placebo, SPN-812 ER 200 mg and SPN-812 ER 400 mg) will be presented, along with 
the corresponding standard error. Each of the active treatment groups (SPN-812 ER 200 and 
400 mg) will be compared with placebo. The p-values, Least Squares (LS) of treatment means, 
differences between the LS treatment means and placebo, and 95% confidence intervals for 
the treatment differences will be computed. 
Sensitivity analysis: The sensitivity analysis assumes that missing ADHD-RS-5 Total Scores 
are missing not at random (MNAR). Placebo-based multiple imputation will be used to fill in 
missing values.  
Secondary: The secondary analyses will be based on the ITT population with missing values 
imputed using multiple imputation assuming MAR. All secondary analyses will be analyzed 
using ANCOVA (except CGI which uses ANOVA on the absolute value of CGI-I at Week 8 
(EOS) on the change from baseline at Week 8 (EOS) with treatment and baseline as fixed 
effect.  
 
Safety Analyses 
Safety analyses will be performed by treatment group based in the safety population. The 
incidence rate, severity, and relationship to SM for all AEs will be summarized by treatment 
group for each System Organ Class and preferred term. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 8 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
Pharmacokinetic and Pharmacogenomic Methods: 
Sampling:  For PK analysis, a maximum of five blood samples will be collected at one or more 
of Visits 3-10. For PGx analysis, a single blood sample will be collected at screening. 
Bioanalytical Analysis: 
Viloxazine concentrations and 5-hydroxy-viloxazine glucuronide concentrations in plasma will 
be determined for all treatments using a validated achiral chromatographic method.  Viloxazine 
concentrations will be reported as viloxazine free base. 
Pharmacokinetic Analysis: 
Plasma concentrations for viloxazine (and 5-hydroxy-viloxazine glucuronide, if applicable) will 
be provided. Population PK data will be pooled across all subjects who participate in this 
optional portion of the study and analyzed using nonlinear mixed-effects modeling methods. 
 
 
  Population PK analyses will be reported 
separately from the clinical study report. 
 
Pharmacogenomics Analysis 
A blood sample will be collected from each individual at screening for PGx analysis. If a given 
subject’s PK data warrant evaluation of PGx, 
 This 
enzyme is involved in the metabolism of viloxazine and genetic variation may affect the 
pharmacokinetics of the drug. The residual DNA will be stored for possible testing of genes 
involved in the efficacy and possible association with particular adverse events of the drug 
(e.g., understand the non-responders to treatment and/or individuals who show unusual safety 
profile). The DNA analysis will not be used for individual genetic characterization and the 
subject identity will be kept confidential.  If PGx testing is performed, individual data will be 
presented as a listing and summaries will be tabulated using descriptive statistics. 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 9 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
TABLE OF CONTENTS 
 
TITLE PAGE ........................................................................................................................ 1 
INVESTIGATOR’S SIGNATURE PAGE............................................................................. 2 
SUPERNUS PHARMACEUTICALS, INC. PROTOCOL APPROVAL PAGE ................... 3 
CLINICAL PROTOCOL SYNOPSIS ................................................................................... 4 
LIST OF ABBREVIATIONS .............................................................................................. 13 
1 
INTRODUCTION..................................................................................................... 15 
1.1 
Background........................................................................................................ 15 
1.2 
Clinical Information ........................................................................................... 15 
1.3 
Study Rationale ................................................................................................. 17 
2 
STUDY OBJECTIVES ............................................................................................ 17 
2.1 
Primary Objective .............................................................................................. 17 
2.2 
Secondary Objectives ....................................................................................... 17 
2.3 
Exploratory Objectives ..................................................................................... 18 
3 
INVESTIGATIONAL STUDY PLAN ....................................................................... 18 
3.1 
Overall Study Design and Plan ........................................................................ 18 
3.2 
RATIONALE FOR STUDY DESIGN .................................................................. 19 
3.3 
STUDY POPULATION........................................................................................ 20 
3.3.1 
Number of Subjects ..................................................................................... 20 
3.3.2 
Inclusion Criteria .......................................................................................... 20 
3.3.3 
Exclusion Criteria ......................................................................................... 20 
3.4 
Completion of Study and Discontinuation of Subjects ................................ 21 
4 
STUDY TREATMENT............................................................................................. 21 
4.1 
Study Medication Identity, Packaging and Labeling..................................... 21 
4.2 
Study Medication Administration .................................................................... 22 
4.3 
Method of Assigning Subjects to Treatment Group ..................................... 22 
4.4 
Blinding .............................................................................................................. 22 
4.5 
Study Medication Handling and Accountability ............................................ 23 
4.6 
Concomitant Medications ................................................................................ 23 
5 
Study Methods ...................................................................................................... 23 
5.1 
Study Visits and Procedures ........................................................................... 23 
5.1.1 
Visit 1 - Screening (Day -28 to -1) ............................................................... 26 
5.1.2 
Visit 2 - Baseline Visit (Day 1) ..................................................................... 26 
5.1.3 
Visit 3 through 9 - Titration (Days 7, 14 [±2 days]) and Maintenance (Days 
21, 28, 35, 42, 49 [±2 days])....................................................................................... 26 
5.1.4 
Visit 10- End-of Study (Day 56) ................................................................... 27 
5.1.5 
Pharmacogenomic Sample Collection ........................................................ 27 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 10 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
5.1.6 
Pharmacokinetic Sub-study-Sample Collection .......................................... 27 
6 
STUDY VARIABLES .............................................................................................. 28 
6.1 
Primary Efficacy Variable ................................................................................. 28 
6.1.1 
ADHD-RS-5.................................................................................................. 28 
6.2 
Secondary Efficacy Variables .......................................................................... 28 
6.2.1 
Clinical Global Impression - Improvement................................................... 28 
6.2.2 
Conners 3..................................................................................................... 29 
6.2.3 
WFIRS-P ...................................................................................................... 29 
6.2.4 
PSI-4-SF....................................................................................................... 30 
6.3 
Safety Variables................................................................................................. 30 
6.4 
Adverse Events ................................................................................................. 30 
6.4.1 
Causality....................................................................................................... 30 
6.4.2 
Recording and Evaluation of Adverse Events ............................................. 31 
6.4.3 
Criteria for Assessing Severity..................................................................... 31 
6.4.4 
Criteria for Assessing Causality................................................................... 31 
6.4.5 
Serious Adverse Events .............................................................................. 32 
6.4.6 
Investigator Responsibilities for Reporting SAEs ........................................ 32 
6.4.7 
Other Events Requiring Immediate Reporting ............................................ 33 
6.4.8 
Sponsor Responsibilities for Reporting SAEs ............................................. 33 
6.5 
Treatment-Emergent Suicidal Ideation ........................................................... 33 
6.5.1 
Columbia Suicide Severity Rating Scale (C-SSRS) .................................... 34 
6.5.2 
Suicide Risk Management Plan................................................................... 34 
6.5.2.1 
Assessment of Suicide Risk ......................................................................... 34 
6.5.2.2 
Acute Suicidal Crisis.................................................................................... 34 
6.5.2.3 
Non-acute Suicidal Risk............................................................................... 34 
6.6 
Clinical Measurements ..................................................................................... 34 
6.6.1 
Laboratory .................................................................................................... 34 
6.6.2 
Vital Signs .................................................................................................... 35 
6.6.3 
Physical Examinations ................................................................................. 35 
6.6.4 
Electrocardiograms (ECGs) ......................................................................... 35 
6.7 
Exploratory Variables ....................................................................................... 35 
7 
STATISTICAL METHODS ..................................................................................... 36 
7.1 
General Considerations.................................................................................... 36 
7.2 
Handling of Missing Data ................................................................................. 36 
7.3 
Analysis Populations ........................................................................................ 36 
7.4 
Demographics and Baseline Analysis ............................................................ 37 
7.5 
Subject Disposition ........................................................................................... 37 
7.6 
Study Medication Exposure and Compliance................................................ 37 
7.7 
Concomitant Medications ................................................................................ 38 
7.8 
Efficacy Analysis ............................................................................................... 38 
7.8.1 
Primary Efficacy Analysis ............................................................................ 38 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 11 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
7.8.1.1 
Primary analysis.......................................................................................... 38 
7.8.1.2 
Sensitivity Analyses..................................................................................... 39 
7.8.2 
Secondary Efficacy Analyses ...................................................................... 39 
7.8.2.1 
Key secondary analyses .............................................................................. 39 
7.8.2.2 
Additional secondary analyses ..................................................................... 40 
7.8.3 
Subgroup Analyses ...................................................................................... 41 
7.8.4 
Exploratory Analyses ................................................................................... 41 
7.9 
Sample Size and Power Considerations ........................................................ 41 
7.10 
Interim Analysis................................................................................................. 41 
7.11 
Pharmacokinetic Analyses............................................................................... 41 
7.12 
Pharmacogenomic Analysis ............................................................................ 41 
7.13 
Safety Analysis .................................................................................................. 42 
8 
DOCUMENTATION ................................................................................................ 42 
8.1 
Adherence to the Protocol ............................................................................... 42 
8.2 
Changes to the Protocol................................................................................... 42 
8.3 
Data Quality Assurance .................................................................................... 43 
8.3.1 
Data Collection ............................................................................................. 43 
8.3.2 
Clinical Data Management........................................................................... 43 
8.3.3 
Database Quality Assurance ....................................................................... 43 
8.3.4 
Bioanalytical Sample Handling .................................................................... 43 
8.4 
Retention of Records ........................................................................................ 44 
8.5 
Auditing Procedures ......................................................................................... 44 
8.6 
Publication of Results....................................................................................... 44 
8.7 
Financing and Insurance .................................................................................. 44 
8.8 
Disclosure and Confidentiality ........................................................................ 44 
8.9 
Discontinuation of Study.................................................................................. 45 
9 
ETHICS ................................................................................................................... 45 
9.1 
Institutional Review Boards ............................................................................. 45 
9.2 
Ethical Conduct of the Study ........................................................................... 45 
9.3 
Investigators and Study Personnel ................................................................. 45 
9.4 
Subject Information and Consent ................................................................... 46 
10 
REFERENCES........................................................................................................ 46 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 12 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
LIST OF TABLES AND FIGURES 
Table 1: Dosing Schedule.................................................................................................. 22 
Table 2:  Schedule of Events and Assessments ............................................................... 25 
Table 3: Clinical Laboratory Tests ..................................................................................... 35 
 
Figure 1: Study Schematic................................................................................................. 19 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 13 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
LIST OF ABBREVIATIONS 
ADHD 
Attention Deficit Hyperactivity Disorder 
ADHD-RS-IV/5 
ADHD Rating Scale- IV/5 
ADR 
Adverse Drug Reaction 
AE 
Adverse Event 
ANOVA 
Analysis of Variance 
ANCOVA 
Analysis of Covariance 
CFR 
Code of Federal Regulations 
CGI-S 
CGI-I 
Clinical Global Impression-Severity of Illness 
Clinical Global Impression-Improvement 
CI 
Confidence interval 
CL/F 
Apparent clearance 
Conners 3 
Conners 3rd edition Rating Scale 
CRA 
Clinical Research Associate 
CRO 
Clinical Research Organization 
CRF 
Case Report Form 
C-SSRS 
Columbia Suicide Severity Rating Scale 
DSM-5 
Diagnostic and Statistical Manual of Mental Disorders-5 
EOS 
End of Study 
ER 
Extended Release 
FDA 
Food and Drug Administration 
FOCP 
Females of Childbearing Potential 
GCP 
Good Clinical Practice 
IAF 
Informed Assent Form 
ICF 
Informed Consent Form 
ICH 
International Conference on Harmonization 
IR 
Immediate Release 
IRB 
Institutional Review Board 
ITT 
Intent to Treat 
IWRS 
LLOQ 
Interactive Web Response System 
Lower Limit of Quantitation 
LS 
Least square 
MAR 
Missing at Random 
MCAR 
Missing Completely at Random 
MedDRA 
Medical Dictionary for Regulatory Activities 
MINI-KID 
Mini International Neuropsychiatric Interview for Children and 
Adolescents 
MMRM 
Mixed Model for Repeated Measures 
MNAR 
PP 
Missing Not At Random 
Per Protocol 
PSI-4-SF 
Parenting Stress Index, Fourth Edition, Short Form 
PGx 
Pharmacogenomics 
PK 
Pharmacokinetics 
PT 
Preferred Term 
QD 
Once a day 
REML 
Restricted Maximum Likelihood 
SADR 
Suspected Adverse Drug Reaction 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SOC 
System Organ Class 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 14 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
SOP 
Standard Operating Procedure 
SM 
Study Medication 
WFIRS-P 
Weiss Functional Impairment Rating Scale – Parent Version 
WHO DD 
World Health Organization Drug Dictionary 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 15 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
1 
INTRODUCTION 
1.1 
Background 
Viloxazine hydrochloride (2-[(2-ethoxyphenoxy) methyl] morpholine hydrochloride) is a 
structurally distinct bicyclic norepinephrine reuptake inhibitor (NRI) with antagonistic activity 
observed at 5-HT7 and 5-HT1B receptors and agonistic activity at 5-HT2B and 5-HT2C 
receptors.  Viloxazine was previously marketed in several European countries as an 
antidepressant.  Supernus is currently developing viloxazine (SPN-812) for potential use 
in the treatment of subjects with attention deficit hyperactivity disorder (ADHD), based on 
the compelling pharmacological properties and favorable safety profile of viloxazine, as 
well as on the current unmet medical need for effective long-acting non-stimulant ADHD 
treatment in children and adolescents. 
Compared to other bicyclic antidepressants, viloxazine has generally been found to be 
well tolerated, with no reports of major toxicity during short or long-term research studies.  
Anticholinergic-like effects and sedation have been less marked and less frequent than 
those of the tricyclic antidepressants, but nausea and vomiting have been common 
complaints with the immediate-release (IR) formulation and may be dose-related. 
Viloxazine is similar in structure to reboxetine and atomoxetine and is a racemic mixture 
of two stereoisomers of similar affinities for many important neurotransmitter receptors.  It 
is an inhibitor of the reuptake of norepinephrine and affects norepinephrine-related 
functional activities, and although its inhibitory action on serotonin re-uptake appears to 
be weak, viloxazine may facilitate serotonin activity pre- or post-synaptically.  Furthermore, 
viloxazine is known to upregulate GABAB binding sites.  These neurotransmitters have 
been implicated in pathophysiology of ADHD, and drugs that are effective in the treatment 
of ADHD act in noradrenergic and dopaminergic systems. 
Viloxazine is rapidly and almost completely absorbed following oral administration to man. 
Unchanged drug is the major component in blood at all times in man and is probably the 
pharmacologically active moiety.  Viloxazine is metabolized and rapidly excreted in the 
urine; there are no known active metabolites. 
1.2 
Clinical Information 
Two Phase 2 studies in ADHD patients, one in adults and one in children, and four 
Phase 1 studies in healthy adults have been conducted with SPN-812 IR or ER. An 
additional open label extension study in children is ongoing. 
Phase 1 Studies 
Phase 1 studies included comparison of SPN-812 ER formulation to an immediate-
release (IR) formulation at single and multiple doses (812P103), evaluation of maximum 
tolerable doses and cardiac safety in a single- and multiple-ascending dose study 
(812P120), and assessment of the effects of food and sprinkling on the relative 
bioavailability of viloxazine (812P105).  In addition, a [14C]-labelled oral IR solution was 
used to examine absorption, metabolism, and excretion of viloxazine in healthy males 
(812P111). 
 
 
  
 
 
  
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 16 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
 
 
  
 
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
  
 
  
 
 
 
Phase 2 Studies 
The proof-of-concept Phase 1/2 study (812P201), compared an IR formulation of SPN-812 
and placebo in a randomized, blinded study, administered three times daily in a dose 
range of 150 to 300 mg/d in 52 adults (26 per treatment) with ADHD.  In addition to 
assessing the safety and tolerability of SPN-812 IR, scores of both the investigator-rated 
and patient-rated Conner’s’ Adult ADHD Rating Scale (CAARS) were collected at weekly 
intervals during the 6-week treatment period.  
 
 
  
The 812P202 study in children with ADHD assessed the effect of SPN-812 ER in reducing 
the symptoms of ADHD as measured by the ADHD Rating Scale-IV (ADHD-RS-IV).  
Subjects aged 6-12 years were randomized in a 1:2:2:2:2 ratio of placebo or active 
treatment (SPN-812 ER 100, 200, 300, or 400 mg) and received three weeks of titration 
at 100 mg/week followed by five weeks of maintenance treatment for a total of eight weeks 
of therapy.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subjects who completed the 812P202 Phase 2 study were eligible to enroll in the open-
label, follow-on study (812P310), which is designed to collect long-term safety and efficacy 
data. 
 
 
 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 17 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
Information and data from clinical studies are available in detail in the SPN-812 ER 
Investigator’s Brochure, version 6.0. 
1.3 
Study Rationale 
The results of the Phase 2 study, 812P202, indicated that SPN-812 ER doses from 200 
to 400 mg/day were effective in the treatment of ADHD in 6-12 year-old children as 
assessed by change from Baseline in ADHD-RS-IV Total Score.  This study seeks to 
confirm the positive efficacy results for the 200 mg and 400 mg dose of SPN-812 ER in a 
larger sample population of children 6-11 years old with ADHD, and to confirm the safety 
and tolerability of those doses in this age group. 
The ADHD-RS-5 is currently the rating scale most commonly used to measure efficacy of 
drug treatment of ADHD and is the primary efficacy measure (Home Version: Child, 
Investigator Administered and Scored) for this study. 
In addition to assessing the effect of SPN-812 ER treatment on ADHD symptom reduction, 
the study aims to explore treatment response within other domains of the disorder, 
including functional impairment, and parental stress (Becker et al., 2011; Wiener et al., 
2016).  ADHD is a chronic, debilitating disorder that affects many aspects of daily life and 
has a substantial burden on family functioning.  Children with ADHD exhibit a number of 
functional impairments, and the motivation in seeking medical treatment typically stems 
from the need to address dysfunction in social, emotional, academic, and familial domains 
(Epstein and Weiss, 2012).  Therefore, optimal medical and behavioral management 
should ideally incorporate treatments that do not just improve symptoms of ADHD, but 
improve broader functioning of a patient, especially in the areas of self-esteem, 
educational achievement, and relationships with peers, teachers, and family.  
2 
STUDY OBJECTIVES  
2.1 
Primary Objective 
 
To evaluate the efficacy of SPN-812 ER compared to placebo as monotherapy for the 
treatment of ADHD in children (6 -11 years). 
2.2 
Secondary Objectives 
Key Secondary 
 
To evaluate the effect of SPN-812 ER compared to placebo as assessed by: 
o Clinical Global Impression – Improvement (CGI-I) scale 
o Conners 3rd edition (Conners 3) – parent, composite T-score 
o Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P) 
Additional Secondary 
 
To evaluate the effect of SPN-812 ER compared to placebo as assessed by: 
o 50% Responder rate based on the ADHD-RS-5 Total score 
o Parenting Stress Index, Fourth Edition, Short Form (PSI-4-SF) 
o ADHD-RS-5 Inattention and Hyperactivity/Impulsivity subscale scores 
o Conners 3 – Self, composite T-score (for ages 8-11 years) 
Safety 
 
To evaluate the safety and tolerability of SPN-812 ER in children with ADHD. 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 18 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
2.3 
Exploratory Objectives 
 
To evaluate the effect of SPN-812 ER compared to placebo as assessed by: 
 
 
 
  
 
 
 
 
 
 
To gain information about: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
INVESTIGATIONAL STUDY PLAN 
3.1 
Overall Study Design and Plan 
This is a multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-group 
study, to evaluate the efficacy and safety of SPN-812 ER as monotherapy for the 
treatment of children 6-11 years old with ADHD.  Approximately 300 subjects will be 
randomized in a 1:1:1 ratio of placebo or one of the two active treatment arms 
(SPN-812 ER 200 or 400 mg).  Following up to four weeks of screening, subjects will be 
randomized and undergo three weeks of titration followed by five weeks of maintenance 
for a total of eight weeks of treatment and total study duration of up to 12 weeks.  The 
study schematic appears in Figure 1. 
Screening (Visit 1):  After administering the informed consent form (ICF) and informed 
assent form (IAF, if applicable), subjects will undergo initial screening evaluation 
including medical and psychiatric history, ECG, vital signs, physical examination, routine 
laboratory assessment, PGx sample collection, and urine drug screen.  ADHD diagnosis 
will be confirmed as will all study inclusion/exclusion criteria.  Eligible subjects will be 
scheduled for a Baseline Visit within 28 days.  Subjects receiving ADHD medication at 
Screening will undergo a washout of at least one week before the Baseline Visit. 
Study Dose Treatment Phase (Visits 2-10): The Treatment Phase will consist of three 
weeks of Titration followed by five weeks of Maintenance until Visit 10/EOS. 
Baseline, Randomization, and Dispensation of Study Medication (SM) (Visit 2): At the 
Baseline Visit, inclusion/exclusion criteria will be reviewed to confirm continued eligibility 
(including urine pregnancy test for Females of Childbearing Potential [FOCP] only).  
Eligible subjects will be randomized and assigned the corresponding blinded dosing kit.  
The titration card of the blinded SM will be dispensed and the first study dose taken. 
Study Dose Treatment: Titration (Visits 2-4): Subjects will return to the clinical site for 
weekly visits to undergo efficacy and safety evaluations, pick up the next dosing card, 
and return the previous card. 
Study Dose Treatment: Maintenance (Visits 5-10): Subjects will return to the clinical site 
for weekly visits to undergo efficacy and safety evaluations, pick up the next dosing card 
(except at Visit 10 the last visit), and return the previous card. 
End of Study (Visit 10): Subjects will return for final evaluation (subjects terminated prior 
to Visit 10 will also undergo EOS evaluations). 
 
a 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 19 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
 
Unscheduled visits may be conducted at the discretion of the investigator throughout the 
study. AE’s will be assessed at all unscheduled visits. 
An optional PK substudy will be conducted between visits 3 and 10, inclusive, to assess 
the PK characteristics of viloxazine (and its metabolite, 5-hydroxy-viloxazine glucuronide, 
if applicable) in this pediatric population.  A total of five blood samples will be taken: pre-
dose and 1, 2, 4, and 6 hours post dose. On the day the pre-dose sample is taken, SM 
must be administered at the site visit. Post-dose samples may be drawn on the same day 
or alternative visit days.  If drawn on alternate visit days, the time the SM was taken that 
day must be consistent with the dose time for the previous two days and the time of dose 
administration must be recorded for all three days. 
Subjects that have successfully completed this study will have the option of enrolling in a 
separate, open-label extension study. 
 
Figure 1: Study Schematic 
 
 
 
3.2 
RATIONALE FOR STUDY DESIGN 
812P303 is a randomized, double-blind, placebo-controlled, multicenter, 3-arm, parallel-
group, pivotal study of SPN-812 ER as monotherapy for the treatment of children ages 
6-11 years with ADHD.  This study is designed to demonstrate efficacy of either 200 or 
400 mg/day SPN-812 ER compared to placebo using change from baseline to the end of 
the study of the ADHD-RS-5 Total Score, the measure most commonly used to assess 
efficacy of drug treatment of ADHD.  Study structure and analysis are typical for a Phase 
3 pivotal trial. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 20 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
3.3 
STUDY POPULATION 
3.3.1  Number of Subjects 
Approximately 300 subjects will be randomized (100 subjects per treatment) in this study. 
3.3.2 Inclusion Criteria   
1. Healthy male or female subjects, 6-11 years of age, inclusive. 
2. Diagnosis of ADHD according to the Diagnostic and Statistical Manual of Mental 
Disorders-5 (DSM-5), confirmed with the Mini International Neuropsychiatric 
Interview for Children and Adolescents (MINI-KID). 
3. Attention Deficit/Hyperactivity Disorder Rating Scale-5, Home Version: Child, 
Investigator Administered and Scored (ADHD-RS-5) score of at least 28. 
4. CGI-S score of at least 4 at screening. 
5. Weight of at least 20 kg. 
6. Free of medication for the treatment of ADHD for at least one week prior to 
randomization and agreement to remain so throughout the study.  
7. Considered medically healthy by the Investigator via assessment of physical 
examination, 
medical 
history, clinical laboratory 
tests, vital signs, and 
electrocardiogram. 
8. Written informed consent obtained from the subject’s parent or legal representative 
and informed assent from the subject, if applicable. 
9. Females of childbearing potential (FOCP) must be either sexually inactive 
(abstinent) or, if sexually active, must agree to use one of the following acceptable 
birth control methods beginning 30 days prior to the first dose, throughout the 
study: 
a. simultaneous use of male condom and intra-uterine contraceptive device 
placed at least four weeks prior to the first study drug administration 
b. surgically sterile male partner 
c. simultaneous use of male condom and diaphragm with spermicide 
d. established hormonal contraceptive 
3.3.3 Exclusion Criteria 
1. Current diagnosis of major psychiatric disorders. Subjects with Major Depressive 
Disorder are allowed in the study if the subject is free of episodes both currently 
and for the last six months. 
2. Current diagnosis of major neurological disorders.  Subjects with seizures or a 
history of seizure disorder within the immediate family (siblings, parents), or a 
history of seizure-like events are excluded from the study. 
3. Current diagnosis of significant systemic disease. 
4. Evidence of suicidality (defined as either active suicidal plan/intent or active 
suicidal thoughts, or more than one lifetime suicide attempt) within the six months 
before Screening or at Screening. 
5. BMI greater than 95th percentile for the appropriate age and gender. 
6. History of an allergic reaction to viloxazine or related drugs. 
7. Any food allergy, intolerance, restriction or special diet that, in the opinion of the 
Investigator, could contraindicate the subject’s participation in this study.  
8. Subjects who received any investigational drug within the longer of 30 days or 5 
half-lives prior to Day 1 dosing of SM. 
9. Any reason which, in the opinion of the Investigator, would prevent the subject from 
participating in the study. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 21 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
10. Positive drug screen at the Screening Visit. A positive test for amphetamines is 
allowed for subjects receiving a stimulant ADHD medication at Screening; the 
subject will be required to discontinue the stimulant for the study, beginning at 
least one week prior to the Baseline Visit. 
11. Pregnancy, breastfeeding, or refusal to practice abstinence or acceptable birth 
control during the study (for female subjects of childbearing potential). 
3.4 
Completion of Study and Discontinuation of Subjects 
Subjects will be considered to have completed the study if they complete all visits up to 
and including Visit 10 (EOS). 
All subjects who discontinue early will complete the procedures listed for Visit 10 (EOS). 
All reasons for screening failure or for failure to continue study eligibility at Baseline after 
successful screening will be recorded. 
The Investigator(s) or subjects themselves may stop SM treatment at any time for safety 
or personal reasons.  A subject is free to withdraw from the study at any time for any 
reason without prejudice to their future medical care by the physician or at the institution.  
The Sponsor may also withdraw the subject at any time in the interest of subject safety.  
The withdrawal of a subject from the study should be discussed where possible with the 
Medical Monitor and/or Clinical Research Associate (CRA) before the subject stops SM.  
Subjects removed from the study for any reason will not be replaced. 
Reasons for subject discontinuation may include: 
 
Withdrawal of consent  
 
Noncompliance  
 
Occurrence of unmanageable AEs 
 
Lost to follow-up 
 
Other 
 
The primary reason for subject discontinuation must be recorded in the subject’s medical 
record and on the eCRF.  If a subject is withdrawn for more than one reason, each reason 
should be documented in the source document and the most medically significant reason 
should be entered on the eCRF. 
If a subject misses doses of SM during this study, the Investigator shall counsel the 
subject/caregiver on the importance of compliance.  If the subject has consistently missed 
doses, he or she may be discontinued from the study at the discretion of the Investigator 
and in consultation with the Medical Monitor; all procedures for discontinuation will be 
followed. 
4 
STUDY TREATMENT 
4.1 
Study Medication Identity, Packaging and Labeling 
Test and reference (matching placebo) products are capsules packaged in a double-blind 
configuration and supplied in labeled blister cards by the Sponsor. 
Each SM blister card will include identical capsules containing placebo or 100 mg of SPN-
812 ER, and will supply a subject with seven days of dosing plus two extra days if needed.  

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 22 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
Each card will be labeled with identification specific to the study and subject (subject 
number and initials). 
4.2 
Study Medication Administration 
Each treatment will be administered as a single oral dose, once-a-day (QD), with or without 
food as either intact capsule, or as capsule content sprinkled on soft food. 
4.3 
Method of Assigning Subjects to Treatment Group 
Eligible subjects will be randomized in a 1:1:1 ratio at Visit 2 (Baseline) and will receive 
either placebo, SPN-812 ER 200 mg/day, or SPN-812 ER 400 mg/day. 
Allocation of study treatment will occur centrally via an interactive web response system 
(IWRS) using a randomization schedule to determine the kit assignment for each subject 
being randomized.  Each SM kit contains eight dosing cards.  One dosing card will be 
given to the subject at each weekly visit.  
The initial dose may be taken at the clinic during the Baseline Visit, with the next dose 
taken the next morning. Subjects will be titrated up at 100 mg/week to the final dose (1:1:1) 
as follows: 
Treatment A: Placebo 
Treatment B: SPN-812 ER 200 mg/day (2 100 mg SPN-812 ER) 
Treatment C: SPN-812 ER 400 mg/day (4 100 mg SPN-812 ER) 
 
Table 1 below presents the details of the dosing schedule for each treatment group. 
Table 1: Dosing Schedule 
 
4.4 
Blinding 
The subject and all personnel involved with the conduct and the interpretation of the study, 
including the Investigators, study site personnel, the Sponsor and Contract Research 
Organization (CRO) clinical staff, including the Medical Monitor, will be blinded to the 
medication codes.  A limited number of Supernus personnel will perform and interpret the 
plasma assays for the population PK analysis and will be aware of these plasma data 
during the study.  These personnel will not have access to the randomization schedule, 
are not associated with the clinical conduct of the study, and will not reveal to any clinical 
personnel involved in the study the treatment to which a subject will be assigned.  
Randomization schedule data will be kept strictly confidential, filed securely by the IWRS 
vendor, and accessible only to authorized persons until the time of unblinding. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 23 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
4.5 
Study Medication Handling and Accountability 
All SM are supplied to the Investigator by the Sponsor. SM supplies must be kept in an 
appropriate secure area (e.g., locked cabinet) and stored according to the conditions 
specified on the SM label. 
Following Sponsor instructions and in compliance with International Conference on 
Harmonization (ICH) E6 as well as local, state, and federal regulations. The Investigator 
and study staff will be responsible for the accountability of all clinical supplies (receiving, 
shipment, dispensing, inventory, and record keeping) in a SM accountability log, a copy 
of which will be collected by Sponsor at the end of the study. 
Under no circumstances will the Investigator allow the SM to be used other than as 
directed by this protocol.  Clinical supplies will not be dispensed to any individual who is 
not enrolled into the study. 
An accurate and timely record of the receipt of all clinical supplies; dispensing of SM to 
the subject; collection of unused supplies; and subsequent return of unused SM to the 
Sponsor must be maintained with dates.  This SM accountability log includes, but may not 
be limited to: (a) documentation of receipt of clinical supplies, (b) SM inventory log, (c) SM 
accountability log, and (d) all shipping service receipts.  Forms may be provided by the 
Sponsor.  Any comparable forms that the study site wishes to use must be approved by 
the Sponsor. 
The supplies and inventory records must be made available, upon request, for inspection 
by the designated representative of the Sponsor, or a representative of the FDA.  The 
assigned Clinical Research Associate (CRA) will review these documents along with all 
other study conduct documents at specified intervals once SM has been received by the 
study site.  All used, partly used, and unused clinical supplies, including empty containers, 
are to be returned to the Sponsor at the conclusion of the study, unless provision is made 
by the Sponsor for destruction of supplies and containers at the study site.  Upon 
completion of SM accountability and reconciliation procedures by study site personnel and 
documentation procedures by Sponsor personnel, SM is to be returned to the Sponsor 
with a copy of the completed SM disposition form. 
4.6 
Concomitant Medications  
Subjects may not be on any prohibited medication as indicated in the Inclusion/Exclusion 
Criteria.  Specific concomitant medication prohibitions include known CYP1A2 substrates 
(e.g., theophylline, melatonin, olanzapine, duloxetine). No additional concomitant 
medications are allowed during the study, with the following exceptions: 
 
Nutritional supplements (e.g. multivitamins, fish oil) 
 
EMLA® or other numbing cream for venipuncture 
 
Common over-the-counter (OTC) therapies for minor transient ailments (e.g. 
acetaminophen for headache, ibuprofen for fever) 
All concomitant medications will be recorded in the eCRF. 
5 
Study Methods 
5.1 
Study Visits and Procedures 
All subjects who are randomized and take the initial dose of SM will be followed according 
to the protocol regardless of the number of doses of SM taken, unless consent for follow-

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 24 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
up is withdrawn.  The Sponsor or the Sponsor’s designee must be notified of all deviations 
from the protocol visit or procedures, except as noted, and these procedures, if applicable, 
will be rescheduled or performed at the nearest possible time to the original schedule.  
Subjects will be instructed to call study personnel to report any abnormalities during the 
intervals in between study visits and to come to the study site if medical evaluation is 
needed and as the urgency of the situation indicates.  For emergency and other 
unscheduled visits to a medical facility other than the study site, medical records will be 
obtained by the Investigator or qualified designee as source data for study follow-up. 
Table 2 represents the Schedule of Events and Assessments for the study. 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 26 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
5.1.1 Visit 1 - Screening (Day -28 to -1) 
Prior to conducting screening procedures, written Informed Consent must be obtained 
from the parent or legal representative; written Informed Assent must also be obtained 
from the subject, if applicable according to local requirements.  Subject screening 
procedures will be performed within 28 days prior to Baseline Visit and may be done on 
more than one day.  Abnormal results on screening laboratory tests may be repeated at 
the discretion of the Investigator.  Subjects receiving ADHD drug therapy at Screening 
must discontinue that therapy for at least one week prior to Visit 2 (Baseline) and must 
remain off the ADHD drug for the duration of the study. 
The following procedures will be performed at Visit 1: 
1. Obtain written informed consent/assent. 
2. Obtain demographic information, medical and psychiatric history 
3. Administer MINI-KID for confirmation of ADHD diagnosis 
4. Perform limited (excluding genitourinary system) physical examination, record 
height and weight 
5. Assess Inclusion/Exclusion criteria 
6. Perform 12-lead ECG 
7. Record vital signs (HR, BP, temperature, and RR) 
8. Collect blood samples for hematology, chemistry, and PGx 
9. Collect urine sample for drug screen 
10. Administer ADHD-RS-5, CGI-S, and C-SSRS 
11. Assess and record concomitant medications 
12. For subjects eligible for study participation based on the above parameters, 
schedule the Baseline Visit, allowing for at least a one-week washout of any ADHD 
drug therapy the subject was receiving at Screening. 
A positive test for amphetamine is allowed for subjects receiving a stimulant ADHD 
medication.  However, the subject must discontinue the stimulant for the duration of the 
study starting at least one week prior to the Baseline Visit. 
5.1.2 Visit 2 - Baseline Visit (Day 1) 
1. Confirm eligibility for the study (Inclusion/Exclusion criteria) 
2. Collect urine and perform pregnancy test (FOCP only) 
3. Randomize (via IWRS) 
4. Administer efficacy and safety scales: ADHD-RS-5, Conners 3 (parent, self [ages 
8-11]), WFIRS-P, PSI-4-SF, CGI-S, and C-SSRS 
5. Record vital signs (HR, BP, temperature, and RR) 
6. Record concomitant medications 
7. Record AEs after SM dosing only 
8. Dispense SM dosing card, observe administration of initial dose (titration starts 
when the first dose of SM is taken). 
 
Study Visits after Visit 2 will have a visit window of ±2 days.  Deviations from this window 
will be recorded in the eCRF but will not require separate notification of the Sponsor. 
5.1.3 Visit 3 through 9 - Titration (Days 7, 14 [±2 days]) and Maintenance (Days 
21, 28, 35, 42, 49 [±2 days]) 
1. Record vital signs (HR, BP, temperature, and RR)  
2. Administer efficacy and safety scales: ADHD-RS-5, CGI-I and C-SSRS  
3. Record concomitant medications 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 27 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
4. Record AEs 
5. Collect returned SM and assess treatment compliance 
6. Dispense SM dosing card 
7. Optional - blood collection for PK substudy, if applicable 
5.1.4 Visit 10- End-of Study (Day 56) 
1. Perform limited (excluding genitourinary system) PE (record only changes from 
baseline), record height and weight 
2. Perform 12-lead ECG 
3. Record vital signs (HR, BP, temperature, and RR) 
4. Collect blood samples for hematology and chemistry 
5. Administer efficacy and safety scales: ADHD-RS-5, Conners 3 (parent, self [ages 
8-11]), WFIRS-P, PSI-4-SF, CGI-I and C-SSRS  
6. Collect urine and perform pregnancy test (FOCP only) 
7. Record concomitant medications 
8. Record AEs 
9. Collect returned SM and assess treatment compliance 
10. Optional - blood collection for PK substudy, if applicable 
11. Determine if subject wants to participate in the open-label extension study 
5.1.5 Pharmacogenomic Sample Collection 
All subjects will have a blood sample taken at Screening for CYP2D6 pharmacogenomic 
testing. Results from individual tests will be used for research purposes only and will not 
be distributed. 
Samples will be identified only by the study subject number to maintain confidentiality. If 
a given subject’s PK data warrant evaluation of PGx, 
 
 
 This enzyme is involved in the metabolism of viloxazine and genetic variation 
may affect the pharmacokinetics of the drug. Samples will be stored for up to 10 years for 
potential future research purposes such as possible testing of genes involved in the 
efficacy and possible association with particular adverse events of the drug (e.g., 
understand the non-responders to treatment and/or individuals who show unusual safety 
profile). The DNA analysis will not be used for individual genetic characterization and the 
subject’s identity will be kept confidential. 
Data from samples will not have diagnostic value and will not be used for individual genetic 
characterization or development of a commercial product. At the end of testing or 10 years, 
any remaining samples will be destroyed. The subject may withdraw consent for 
pharmacogenomic testing at any time; if consent is withdrawn, the subject’s sample will 
be destroyed. 
5.1.6 Pharmacokinetic Sub-study-Sample Collection 
Participation in the PK Sub-study is optional.  All blood samples for PK analysis will be 
drawn at the clinical site.  A maximum of five blood samples (4 mL each) will be taken for 
PK analysis over the course of the study.  Blood may be drawn for quantitative PK analysis 
during Visits 3-10. 
At one of these visits, subjects will arrive at the clinic in the morning prior to taking their 
morning dose.  A PK sample will be drawn pre-dose, after which the dose will be 
administered in the clinic.  Post-dose PK samples will be taken at approximately 1, 2, 4, 
and 6 hours after the administered dose.  Collection of the post-dose samples may be on 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 28 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
the same visit or an alternate visit (dosing at home) if the previous two doses were taken 
at approximately the same time and the times for that day and the previous two days were 
recorded. 
Blood samples will be collected and processed as per instructions in the Laboratory 
Manual.  The following excursion windows are permitted: 
 
Pre-dose: 
up to 30 minutes before dose 
 
1-2 hours: 
± 15 minutes 
 
4 and 6 hours: 
± 30 minutes 
 
6 
STUDY VARIABLES 
6.1 
 Primary Efficacy Variable 
6.1.1 ADHD-RS-5 
The primary endpoint in this study is the CFB to EOS in the ADHD-RS-5 Total Score.  
The ADHD-RS-5 is an ADHD-specific rating scale designed and validated to assess 
current ADHD symptomatology as described in the fifth edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5).  The scale consists of 18 items that 
directly correspond to the 18 DSM-5 symptoms and are further subdivided into two 
subscales: Hyperactivity/Impulsivity and Inattention (DuPaul, 2016).  The ADHD-RS-5 
scale rates the frequency and severity of each symptom on a 4-point Likert-type scale 
from 0 (none) to 3 (severe) and allows assessment of functional impairments linked to 
each symptom dimension.  The ADHD-RS-5 rating scale is one of the most commonly 
used measures of drug efficacy in the treatment of ADHD and is the primary outcome 
measure for this study.  The ADHD-RS-5 Home Version: Child instrument will be 
administered and scored by Investigator at each weekly visit from Baseline through EOS. 
6.2 
Secondary Efficacy Variables 
The key secondary efficacy variables include: 
a) CGI-I 
b) Conners 3 – Parent, composite T-score 
c) WFIRS-P average score 
 
Additional secondary variables include: 
a) Proportion of responders with 50% improvement in the ADHD-RS-5 Total score 
(50% Responder rate) 
b) PSI-4-SF 
c) ADHD-RS-5 Inattention and Hyperactivity/Impulsivity subscale scores 
d) Conners 3 – Self, composite T-score (for ages 8-11 years) 
 
6.2.1 Clinical Global Impression - Improvement 
The CGI scale was developed to provide a brief, stand-alone assessment of the clinician’s 
view of a subject’s global functioning prior to and after administration of a SM (Guy 1976).  
The Clinical Global Impression – Severity of Illness (CGI-S) is a single item clinician rating 
of clinician’s assessment of the severity of the ADHD symptoms in relation to the clinician’s 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 29 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
total experience with patients with ADHD.  The Clinical Global Impression – Improvement 
Scale (CGI-I) is an assessment of how much the patient’s illness has improved or 
worsened relative to a baseline state at the beginning of treatment. Both CGI-S and CGI-
I are rated on a 7-point scale of 1 to 7 with 7 being “extremely ill” or “very much worse”, 
respectively.  Successful therapy is indicated by a lower overall score in subsequent 
testing. 
 
CGI-S will be evaluated by the Investigator at Screening and Baseline on a 7-point 
scale with 1=Normal,    2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly 
ill, 6=Severely ill, and 7=Extremely ill.    
 
CGI-I, relative to the condition at baseline, will be evaluated by the Investigator at 
each post-baseline visit on a 7-point scale with 1=Very much improved, 2=Much 
improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much 
worse, and 7=Very much worse.   
 
6.2.2 Conners 3 
The Conners 3rd Edition™ (Conners 3) is a focused diagnostic tool for assessment of 
ADHD and associated learning, behavior, and emotional problems in children ages 6 to 
18 years (Sparrow, 2010). The scale is based on the solid findings and key elements of 
its predecessor, the Conners' Rating Scales–Revised (CRS–R™), but offers a more 
refined assessment of ADHD and comorbid disorders (e.g., oppositional defiant disorder 
and conduct disorder). The Conners 3 instrument includes items related to inattention, 
hyperactivity, and impulsivity, as well as assessments of executive functioning, learning 
problems, and relationships. Like previous versions, the Conners 3 combines teacher, 
parent, and student reports to provide a particularly detailed and comprehensive 
evaluation of student behavior as observed in different settings. Teacher, parent, and self-
report (for 8-18y.o.) rating scales are all available in long and short versions.  The short 
forms of Parent, Teacher, and Self Reports of Conners 3 are comprised (respectively) of 
45, 41, and 41 items.  All Conners 3 scale versions are scored on a 4-point scale (0-3), 
where a higher score indicates more severe symptom presentation. 
The Conners 3 scales will be administered at Visit 2 (Baseline) and at Week 8 (EOS) 
according to subjects’ age as follows: 
 
Age 6-11:  
Conners 3 – Parent: Short (Conners 3-PS) 
 
Age 8-11 only: 
Conners 3 – Self-Report: Short (Conners 3-SRS) 
 
6.2.3 WFIRS-P 
The Weiss Functional Impairment Rating Scale (WFIRS) instrument evaluates ADHD-
related functional impairment (Gajria, 2015; Thompson, 2017).  This scale allows the 
clinician to assess to what degree a patient’s behavior and emotional problems affect 
his/her ability to accomplish daily tasks and interactions and helps to identify specific areas 
of difficulty.  The scale has been validated in the ADHD population; the parent-based 
version (WFIRS-P) completed by the parent/guardian of a child is used in this study and 
comprises 50 items grouped into six domains: Family, School (learning and behavior), Life 
Skills, Child’s Self-Concept, Social Activities, and Risky Activities.  The items relate to the 
past month and are scored using a 4-point Likert scale. Higher WFIRS-P scores indicate 
more severe functional impairment.   
This instrument will be completed at Baseline and EOS by the parent/caregiver. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 30 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
6.2.4 PSI-4-SF 
The Parenting Stress Index, Fourth Edition (PSI-4) questionnaire evaluates the magnitude 
of stress in the parent-child relationship based on the parent’s perception of the child’s 
characteristics, the personal characteristics of the parent, and the interaction between the 
parent and the child (Abidin, 1995).  The short form (PSI-4-SF) of the PSI-4 consists of 36 
items divided into three domains: parental distress, parent-child dysfunctional interaction, 
and difficult child.  The PSI-4-SF scale was developed for parents of children ages 1 month 
to 12 years.   
This scale will be completed at Baseline and at EOS by the parent/caregiver. 
6.3 
Safety Variables  
The safety variables for the study are AEs, clinical laboratory test results, vital signs, ECG 
results, and treatment-emergent suicidal ideation. 
Investigators are responsible for monitoring the safety of subjects who have entered this 
study and for alerting Supernus or its designee to any event that seems unusual, even if 
this event may be considered an unanticipated benefit to the subjects. 
Safety assessments include monitoring, evaluation, and recording of all concomitant 
medications, and the evaluation of AEs, clinical laboratory test results, vital signs and 12-
lead ECGs, C-SSRS, and the performance of physical examinations as detailed in the 
Schedule of Events and Assessments. 
6.4 
Adverse Events 
As defined by the ICH Guideline for Good Clinical Practices (GCP), an adverse event (AE) 
is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with treatment. 
An AE can be: 
• 
Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product. 
• 
Any new disease, intercurrent injuries, or exacerbation of an existing disease. 
• 
Any deterioration in a laboratory value or other clinical test (e.g., ECG) that results in 
symptoms, a change in treatment, or discontinuation from SM. 
• 
Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline. 
Surgical procedures are not AEs; they are therapeutic measures for conditions that require 
surgery.  The condition for which the surgery is required is an AE, if it occurs or is detected 
during the study period. 
6.4.1 Causality 
Adverse events may be categorized as either Adverse Drug Reactions or Suspected 
Adverse Drug Reactions based on their relationship to SM and the degree of certainty 
about causality. 
Suspected adverse drug reactions (SADRs) are a subset of adverse events for which 
there is evidence to suggest a causal relationship between the drug and the AE, i.e., there 
is a reasonable possibility that the drug caused the adverse event. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 31 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
Adverse drug reactions (ADRs) are a subset of all SADRs for which there is reason to 
conclude that the drug caused the event. 
6.4.2 Recording and Evaluation of Adverse Events 
All subjects who are screened (Visit 1) will be questioned regarding the occurrence of AEs.  
At each contact with the subject, the investigator must seek information on AEs by specific 
questioning and, as appropriate, by examination.  Information on all AEs should be 
recorded immediately in the source document, and also in the appropriate adverse event 
module of the eCRF.  All clearly related signs, symptoms, and abnormal diagnostic 
procedures results should be recorded in the source document, though they may be 
grouped under one diagnosis.  For example, fever, elevated WBC, cough, abnormal chest 
X-ray, etc., can all be reported as “pneumonia”. 
All AEs occurring after screening and throughout the study period must be recorded.  A 
treatment-emergent adverse event (TEAE ) is defined as an AE with a start date on or 
after the first dose of study drug is taken, or that worsened following first administration of 
study drug.  All AEs in this study will be recorded after administration of SM, therefore all 
will be treatment-emergent.  The clinical course of each AE should be followed until 
resolution or until, in the medical judgment of the Investigator, the event has stabilized or 
is assessed as chronic. 
The Investigator is responsible for evaluating AEs and determining the following: 
• 
Serious vs. Non-serious: Is the event a Serious Averse Event (SAE)? 
• 
Causality: Was AE related or possibly related to the SM? 
• 
Severity: How pronounced is the incapacity/discomfort caused by an AE? 
6.4.3 Criteria for Assessing Severity 
The Investigator will evaluate the comments of the subject and the response to treatment 
in order that he or she may judge the true nature and severity of the AE.  Severity refers 
to the accumulated intensity of discomfort/impairment of health since the last recording of 
AEs and will be assessed according to the following criteria: 
• Mild: 
Awareness of sign, symptom, or event, but easily tolerated 
• Moderate: Discomfort enough to interfere with usual activity and may warrant 
intervention 
• Severe:    Incapacitating with inability to do usual activities or significantly 
affects clinical status and warrants intervention 
The criteria for assessing severity are different from those used for seriousness. 
6.4.4 Criteria for Assessing Causality 
The Investigator is responsible for determining the relationship between the administration 
of SM and the occurrence of an AE as not suspected or as a suspected reaction to SM.  
These are defined as follows: 
Not suspected: The temporal relationship of the AE to SM administration makes a causal 
relationship unlikely, or other drugs, therapeutic interventions, or underlying conditions 
provide a sufficient explanation for the observed event.  
• Not related:  Temporal relationship to SM administration is missing or 
implausible, or there is an evident other cause. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 32 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
• Unlikely related:  Temporal relationship to SM administration makes a causal 
relationship improbable; and other drugs, chemicals, or underlying disease 
provide plausible explanations. 
Suspected: The temporal relationship of the AE to SM administration makes a causal 
relationship possible, and other drugs, therapeutic interventions, or underlying 
conditions do not provide a sufficient explanation for the observed event.  
• Possibly related:  Temporal relationship to SM administration is plausible, but 
concurrent disease or other drugs or chemicals could also explain event.  
Information on drug withdrawal may be lacking or unclear.  This will be reported 
as a Suspected Adverse Drug Reaction (SADR). 
• Definitely related: Temporal relationship to SM administration is plausible, and 
concurrent disease or other drugs or chemicals cannot explain event.  The 
response to withdrawal of the medication (dechallenge) should be clinically 
plausible. 
 
The 
event 
must 
be 
definitive 
pharmacologically 
or 
phenomenologically, using a satisfactory rechallenge procedure if necessary.  
This will be reported as an Adverse Drug Reaction (ADR). 
6.4.5 Serious Adverse Events 
Adverse events are classified as serious or non-serious.  An AE or ADR is considered 
“serious” if, in the view of either the investigator or Sponsor, it results in one of the following 
outcomes:  
• 
death 
• 
life-threatening AE (i.e., the subject was at immediate risk of death from the AE 
as it occurred.  This does not include an event that, had it occurred in a more 
severe form or was allowed to continue, might have caused death.) 
• 
in-patient hospitalization or prolongation of existing hospitalization 
• 
persistent or significant disability or incapacity or substantial disruption of the 
ability to conduct normal life functions 
• 
a congenital anomaly or birth defect 
• 
an important medical event 
Important medical events are those that may not be immediately life threatening or result 
in death or hospitalization, but are clearly of major clinical significance.   They may 
jeopardize the subject, and may require intervention to prevent one of the other serious 
outcomes noted above.  For example, drug overdose or abuse, blood dyscrasias, a 
seizure that did not result in in-patient hospitalization or intensive treatment for allergic 
bronchospasm in an emergency department would typically be considered serious. 
6.4.6 Investigator Responsibilities for Reporting SAEs 
The Investigator must immediately report to the Sponsor all SAEs, regardless of whether 
the Investigator believes they are drug related. 
All SAEs must be reported to the Drug Safety Contact within 24 hours of first becoming 
aware of the SAE.  The Investigator must complete an SAE Form and include a detailed 
description of the SAE, as well as other available information pertinent to the case (e.g., 
hospital records, autopsy reports and other relevant documents).  The investigator will 
keep a copy of this SAE Report form on file at the study site. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 33 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
The Investigator or study physician, after thorough consideration of all facts that are 
available, must include an assessment of causality of an AE to SM in the report to the 
Sponsor. 
Follow-up information, or new information available after the initial report, should be 
actively sought and reported to the Sponsor, as it becomes available, using the SAE 
Report Form.   
 
 
 
  
6.4.7 Other Events Requiring Immediate Reporting 
The Investigator must report a pregnancy that occurs in a subject during a clinical study 
to the Drug Safety Contact within 24 hours of first becoming aware of the event.  
Pregnancy should be reported on a Pregnancy Report Form.  The Investigator should 
discuss the case with the Medical Monitor; the Investigator must follow any pregnant 
subject for 3 months after the child is born.  Any AEs concerning the pregnancy of the 
subject during pregnancy or the child after birth must be documented and reported to the 
Sponsor. 
Acute suicidal crisis or clinically significant suicidal behavior or ideation should be reported 
to the Drug Safety Contact within 24 hours of first becoming aware of the event. 
6.4.8 Sponsor Responsibilities for Reporting SAEs 
The Sponsor will inform Investigators and regulatory authorities of reportable events, in 
compliance with applicable regulatory requirements, on an expedited basis (i.e., within 
specific timeframes).  For this reason, it is imperative that study sites submit SAE 
information to the Sponsor in the manner described above. 
Investigators must comply with the applicable regulatory requirements related to the 
reporting of SAEs to the Institutional Review Board (IRB).  Investigators must also submit 
the safety information provided by the Sponsor to the IRB unless the country legal 
regulation requires that the Sponsor should be responsible for the safety reporting to the 
IRB. 
It is the responsibility of the Sponsor to notify all participating investigators, in a written 
IND safety report, of any SADR that is both serious and unexpected.  The Sponsor will 
also notify participating investigators of any findings from other sources (other studies, 
animal and in vitro testing, etc.) that suggest a significant risk for human subjects.  Such 
findings will typically lead to safety-related changes in the study protocol, Informed 
Consent, and/or Investigator’s Brochure. 
6.5 
Treatment-Emergent Suicidal Ideation 
Prospective assessment of suicidal ideation and suicidal behavior is a mandatory part of 
the safety evaluations for any drug developed for a psychiatric indication (FDA Guidance 
for Industry: Prospective Assessment of Occurrence in Clinical Trials: Suicidal Ideation 
and Behavior, 2012).  In this study, the initial evaluation of subjects will be conducted prior 
to enrollment to assess lifetime suicidal ideation and to identify subjects who must not 
participate in the trial due to pre-existing suicidality risk.  The assessment will then be 
repeated at each subsequent study visit to monitor the occurrence of new suicidal and 
self-injurious tendencies. 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 34 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
6.5.1 Columbia Suicide Severity Rating Scale (C-SSRS) 
Assessment of suicidal ideation and behavior will be conducted using the Columbia-
Suicide Severity Rating Scale (C-SSRS).  The C-SSRS is an FDA-recommended 
prospective assessment instrument that directly classifies suicidal ideation and behavior 
events into 11 preferred categories, including 5 levels of suicidal ideation, 5 levels of 
suicidal behavior, and the category of self-injurious behaviors with no suicidal intent.   
The instrument has been validated and used successfully in both children and adolescent 
patients with various psychiatric disorders that do not involve cognitive impairment.  The 
C-SSRS outcomes that can be used for clinical management and safety monitoring are 
suicidal lethality rating, suicidal ideation score, and suicidal ideation intensity rating. 
6.5.2 Suicide Risk Management Plan 
The protocol procedures related to clinical care of patients with treatment-emergent 
suicidal ideation and behavior must be implemented to ensure proper management of the 
event and protection of subject’s safety.  If a disclosure of suicidal ideation is revealed as 
part of the C-SSRS questionnaire or when a subject spontaneously expresses that he/she 
may be a threat to him/herself, the study team should be prepared to quickly evaluate the 
event and to determine the appropriate course of action. 
6.5.2.1 Assessment of Suicide Risk 
Any indication of suicidal ideation should be evaluated as soon as possible by 
appropriately trained staff. The Investigator is responsible for making the final judgment 
regarding potential suicide risk and need subsequent action.  
6.5.2.2 Acute Suicidal Crisis 
A person evaluated as being at high risk should be transferred to an immediate care 
facility. The Investigator will guide intervention as clinically indicated and follow up with 
the subject within one week and/or refer him/her to a qualified mental health professional. 
6.5.2.3 Non-acute Suicidal Risk 
The Investigator will conduct safety planning with the subject and will follow up within one 
week. 
 
Reference materials for subjects and caregivers should include lists of mental health 
organizations and professionals, outpatient behavioral services, local crisis and peer 
support groups and Suicide/Crisis Hotlines. 
6.6 
 Clinical Measurements 
6.6.1 Laboratory  
All clinical laboratory tests will be performed by a central laboratory as specified in the 
reference binder. 
Details for collecting, handling, and shipping samples (including shipment addresses) will 
be detailed in a separate clinical laboratory manual.  The Schedule of Events and 
Assessments (Table 2) shows the time points at which blood and urine samples will be 
collected for clinical laboratory tests (and plasma concentration levels for those subjects 
that choose to participate in the PK substudy). 
Table 3 presents the clinical laboratory tests to be performed. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 36 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
 
 
 
 
 
 
7 
STATISTICAL METHODS 
7.1 
General Considerations 
All statistical analysis will be performed using SAS version 9.2 or higher by 
, which is 
the designated CRO. 
 will be responsible for developing a unique program for each 
TLF to create a TLF report and deliver to Supernus at the completion of the study.   
All tabulations of analysis results will include summaries for the following three treatments: 
SPN-812 ER 400 mg, SPN-812 ER 200 mg, and placebo. 
Where appropriate, variables will be summarized descriptively (frequency count and 
percent for categorical variables, and number of subjects (n), mean, standard deviation 
(SD), median, minimum, and maximum for continuous variables). 
The data summaries will be accompanied by individual subject data listings, as specified 
in Sections 16.2 and 16.4 of ICH Guidance E3, sorted by unique subject identifier.  All 
data available from the electronic case report forms (eCRFs) will be listed.  Unscheduled 
measurements will be excluded from the descriptive statistics and statistical analysis but 
will be included in listings. 
Categorical variables will be analyzed using categorical response methods such as 
Pearson’s Chi-square test.  If expected frequencies are less than 5 in a given cell, then 
exact testing techniques will be used. 
Complete details of the statistical analysis will be provided in a separate statistical analysis 
plan (SAP).  The statistical analysis methods described in the SAP will supersede the 
statistical methods described in this protocol. 
7.2 
Handling of Missing Data 
With respect to the primary analysis, missing ADHD-RS-5 Total Scores will be assumed 
to be missing at random (MAR), that is, given the observed data, the reason for the missing 
data does not depend on the unseen data.  The Mixed Model for Repeated Measures 
(MMRM) method, implemented via SAS® PROC MIXED (SAS/STAT Software), will be 
used for handling missing ADHD-RS-5 Total Scores under MAR assumption. Under MAR, 
the propensity for a data point to be missing is not related to the missing data, but is related 
to some of the observed data.  
The sensitivity analysis for the primary endpoint will be performed by assuming that 
missing ADHD-RS-5 Total Scores are missing not at random (MNAR) meaning that the 
probability that an observation is missing may depend on its underlying unobserved value.  
For analysis of secondary endpoints, missing values will be assumed as MAR. 
For safety analyses, missing dates for AEs and non-study medication use will be imputed 
as described in the SAP. Missing data for all other safety endpoints will not be imputed. 
7.3 
Analysis Populations 
 
The Randomized population will include all enrolled subjects who had a baseline 
visit and are randomized via the IWRS. 
 
e
 
e
 
 R

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 37 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
 
The Intent-to-Treat (ITT) population for efficacy will include all randomized subjects 
who took at least one dose of study medication and had a Baseline and ≥1 post-
randomization ADHD-RS-5 assessment. Subjects will be analyzed according to 
the treatment to which they were randomized. 
 
The Per Protocol (PP) population consists of all subjects in the ITT population who 
completed all 10 visits with no missing ADHD-RS-5 assessments and no major 
protocol violations. Subjects will be analyzed according to the treatment they 
actually received. 
 
The Safety Population consists of all subjects randomized into the study who 
receive at least one dose of SM. Subjects will be analyzed according to the 
treatment they actually received. 
 
The PK population will include all subjects in the safety population who had ≥1 PK 
sample that is not below the LLOQ. 
7.4 
Demographics and Baseline Analysis 
Demographic/baseline variables including age, age group, sex, ethnicity, race, height and 
weight at screening, and BMI will be summarized using descriptive statistics for continuous 
variables and using counts and percentages for categorical variables.  The descriptive 
summary will be presented by treatment group for the randomized population and ITT 
population. 
Baseline disease characteristics will include ADHD-RS-5 Total score, subscale scores, 
and hyperactivity/impulsivity score. These will be summarized for the ITT population. 
Baseline comparability among the treatment groups will be summarized using a chi-
square test for categorical variables and F-test for continuous variables. P-values will be 
used for descriptive purposes only. 
7.5 
Subject Disposition 
A disposition of subjects will include the number and percentage of subjects in each of the 
following categories: 
 
Subjects in the ITT population 
 
Subjects in the PP population 
 
Subjects in the safety population 
Within each of the previous categories, the number and percentage of subjects who 
completed and discontinued from the study and the primary reason for early 
discontinuation will be summarized.  The reason for early discontinuation may include any 
of the following: 
 
Withdrawal of consent  
 
Noncompliance  
 
Occurrence of unmanageable AEs 
 
Lost to follow-up 
 
Other 
 
7.6 
Study Medication Exposure and Compliance 
Duration of exposure is defined as the total number of days a subject is exposed to any 
study treatment. This will be calculated for each subject by taking the difference between 
the date of last dose minus the date of the first dose, plus 1 (date of last dose minus date 
of first dose +1). 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 38 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
Duration of treatment exposure will be summarized by duration category and will also be 
summarized using descriptive statistics (n, mean, SD, median, minimum, and maximum). 
Percent of study drug compliance is defined as {(number of capsules dispensed minus 
number of capsules returned) /4 × (date of last dose minus date of first dose + 1)}* 100%. 
For each treatment, SM compliance will be summarized by compliance category (<80%, 
80-120%, and >120%) and number of subjects in each compliance category.  Study 
medication compliance will also be summarized as a continuous variable using descriptive 
statistics (n, mean, standard deviation, median, minimum, and maximum) for each 
treatment. 
Summaries of treatment compliance and exposure will be presented separately for the 
Titration Period, Maintenance Period, and combined Titration and Maintenance Periods. 
7.7 
Concomitant Medications 
Concomitant medications will be assigned an 11-digit code using the World Health 
Organization Drug Dictionary (WHO DD) drug codes.  Concomitant medications will be 
further coded to the appropriate Anatomical-Therapeutic-Chemical (ATC) code indicating 
therapeutic classification.  A tabular summary of concomitant medications by drug class 
will be presented for the safety population. 
7.8 
Efficacy Analysis 
7.8.1 Primary Efficacy Analysis 
7.8.1.1 Primary analysis 
The primary efficacy variable, change from baseline in ADHD-RS-5 Total Score to Week 
8 (EOS), will be analyzed using MMRM, which assumes that missing data are MAR. The 
model will include fixed effect terms for baseline ADHD-RS-5 Total Score, age group, 
treatment, visit, and treatment-by-visit interaction as independent variables. The model 
parameters will be estimated using restricted maximum 
likelihood method with 
unstructured variance-covariance matrix and Kenward-Roger approximation to estimate 
denominator degrees of freedom. In case there is a convergence problem in the MMRM 
model with the unstructured variance-covariance matrix, the first (co)variance structure 
which does not have convergence problem will be used for the analysis from the following 
ordered list: 1) Toeplitz, 2) Autoregressive of order 1, and  3) Compound symmetry.  
 
The adjusted mean (LS Mean) of CFB to EOS for ADHD-RS-5 Total Score for each 
treatment group (Placebo, SPN-812 ER 200 mg and SPN-812 ER 400 mg) will be 
presented, along with the corresponding standard error. Each of the treatment groups 
(SPN-812 ER 200 mg and 400 mg) will be compared with the Placebo. The p-values, 
Least Squares (LS) of treatment means, differences between the LS treatment means and 
placebo, and 95% confidence intervals for the treatment differences will be computed. 
To maintain the Type I error rate at 5% level, a sequential testing (Westfall et al,1999) of 
the null hypotheses H01: No treatment mean difference between SPN-812 ER 400 mg 
group and placebo group and H02: No treatment mean difference between SPN-812 ER 
200 mg group and placebo group will be performed. If H01 is not rejected, then H02 will not 
be tested and the conclusion will be that neither dose groups are efficacious. If H01 is 
rejected, then H02 will be tested. If H02 is rejected then it will be concluded that both SPN-
812 ER 400 mg and SPN-812 ER 200 mg are superior to placebo. If H01 is rejected and 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 39 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
H02 is not rejected then it will be concluded that only SPN-812 ER 400 mg is superior to 
placebo. 
7.8.1.2 Sensitivity Analyses 
The sensitivity analysis assumes that missing ADHD-RS-5 Total Scores are MNAR. 
Placebo-based multiple imputation will be used to fill in missing values. This approach 
may be considered “worst-case” sensitivity analyses as it assumes that after 
discontinuation, subjects from the active treatment arms would adopt the outcome model 
estimated from the placebo arm. The placebo-based imputation will be implemented as 
described in the SAP. 
7.8.2 Secondary Efficacy Analyses 
The secondary analyses will be based on the ITT population with missing values imputed 
using multiple imputation assuming MAR. 
 
All secondary analyses will be analyzed using ANCOVA (except CGI which uses ANOVA 
on the absolute value of CGI-I at Week 8 (EOS) on the change from baseline at Week 8 
(EOS) with treatment and baseline as fixed effect. Each of the treatment groups (SPN-
812 ER 200 mg and 400 mg) will be compared with the Placebo. The p-values, Least 
Squares means of the treatment groups, differences between the LS treatment means 
and placebo (SPN-812 ER 200 mg minus Placebo and SPN-812 ER 400 mg minus 
Placebo), and 95% confidence intervals for the treatment differences will be computed. 
7.8.2.1 Key secondary analyses 
The analyses of key secondary objectives will be conducted on the following sequentially 
ordered endpoints for testing: 1) CGI-I, 2) Conners 3 – Parent composite T-score, and 
3) WFIRS-P. 
To preserve the overall type I error rate at 0.05 for the key secondary endpoints, a 
sequential testing procedure will be used with the following features.  
First, only dose or doses that are significantly different from placebo for the primary 
endpoint will be tested for secondary endpoints. If the primary endpoint analysis does not 
show a rejection of H01 (i.e., the 400 mg is not superior to placebo) then no multiplicity 
adjustment will be performed for any of the key secondary endpoints.  If the primary 
endpoint analysis indicates that only 400 mg dose is superior to placebo (only H01 is 
rejected), no multiplicity adjustment is required. Otherwise, multiplicity adjustment will be 
performed as in the following. 
The first of the secondary endpoints (CGI-I) will be used to test each treatment group to 
placebo using a sequential testing of the null hypotheses H01: No treatment mean 
difference between SPN-812 ER 400 mg group and placebo group and H02: No treatment 
mean difference between SPN-812 ER 200 mg group and placebo group will be 
performed. If H01 is not rejected, then H02 will not be tested and the conclusion will be that 
neither dose groups are efficacious. If H01 is rejected, then H02 will be tested. If H02 is 
rejected, then it will be concluded that both SPN-812 ER 400 mg and SPN-812 ER 200 mg 
are superior to Placebo. If H02 is not rejected, then it will be concluded that only SPN-812 
ER 400 mg is superior to placebo. Then, the second secondary endpoint (Conners 3) will 
be tested in the same manner but only using those doses that were retained from the 
primary and the first secondary endpoint. Finally, the third key secondary endpoint 
(WFIRS-P) will be tested in the same manner but only using those doses that were 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 40 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
retained from the primary, the first key secondary endpoint, and the second key secondary 
endpoints. 
a) CGI-I – The absolute value of CGI-I at EOS will be analyzed using ANCOVA with 
fixed effects for treatment and baseline as a covariate. To compare the treatment 
groups, the difference in LS means (SPN-812 ER 200 mg minus Placebo and 
SPN-812 ER 400 mg minus Placebo) will be presented along with the 95% 
confidence interval (CI) around the difference and p-value. 
b) Conners 3 - Parent - A composite T-score will be calculated by averaging over the 
six domains, and the change from baseline to Week 8 (EOS) in the composite T-
score will be analyzed using ANCOVA model with fixed effects for treatment and 
baseline as a covariate. Each of the treatment groups (SPN-812 ER 200 mg and 
400 mg) will be compared with the Placebo. The p-values, Least Squares means, 
differences between the LS treatment means and placebo, and 95% confidence 
intervals for the treatment differences will be computed. 
c) WFIRS-P - The change from baseline in WFIRS-P to Week 8 (EOS) will be 
analyzed using ANCOVA model with fixed effects for treatment and baseline as a 
covariate. Missing Subscale scores and Total Score will be handled using multiple 
imputation under MAR assumption for inferential analyses. Each of the treatment 
groups (SPN-812 ER 200 mg and 400 mg) will be compared with the Placebo. The 
p-values, LS means of treatment groups, differences between the LS means and 
placebo, and 95% confidence intervals for the treatment differences will be 
computed. 
 
7.8.2.2 Additional secondary analyses 
Additional secondary analyses of the secondary efficacy variables will include: 
a) 50% Responder rate for ADHD-RS-5 - Percent reduction will be calculated as: % 
reduction = 100*(ADHD-RS-5 Total Score at Week 8 (EOS) - Baseline ADHD-RS-5 
Total Score)/Baseline ADHD-RS-5 Total Score. The proportion of responders will be 
presented for each treatment group. The 2-sided 95% CI around the difference in 
proportions (SPN-812 ER 200 mg minus Placebo, SPN-812 ER 400 mg minus 
Placebo) and the p-value from Pearson’s Chi-squared Test or Fisher’s Exact Test  will 
be presented. 
b) PSI-4-SF - The change from baseline in PSI-4 total score to Week 8 (EOS) will be 
analyzed using ANCOVA model with fixed effects for treatment and baseline as a 
covariate. Each of the treatment groups (SPN-812 ER 200 mg and 400 mg) will be 
compared with the Placebo. The p-values, LS means of treatment groups, differences 
between the LS means and placebo will be presented. 
c) ADHD-RS-5 Inattention and Hyperactivity/Impulsivity subscales - The primary analysis 
for ADHD-RS-5 Total score will be repeated for the change from baseline to EOS in 
ADHD-RS-5 Inattention and the change from baseline to Week 8 (EOS) in 
Hyperactivity/Impulsivity subscales.  
d) Conners 3 - Self – The analysis for Conners 3 - Parent will be repeated for Self scores. 
The key secondary analyses will be repeated for the per protocol population for 
supplementary analyses. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 41 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
7.8.3 Subgroup Analyses 
The primary and key secondary efficacy variable analyses may be repeated by the 
following subgroups to explore the heterogeneity of treatment effect: 
a) Gender (male, female) 
b) Age (6-9 years, 10-11 years) 
c) Race (white, non-white) 
7.8.4 Exploratory Analyses 
Exploratory analyses of the key exploratory efficacy variables will include: 
 
 
 
 
 
 
 
 
 
 
 
7.9 
Sample Size and Power Considerations 
Seventy-two subjects per treatment group in the ITT population will yield 90% power at a 
significance level of 0.05 (two-sided) using a two-sample t-test with equal allocation to the 
treatment groups.  This assumes an effect size of 0.547, observed in the comparison of 
SPN-812 200 mg and placebo in the SPN-812 Phase IIb study (based on the CFB to 
endpoint in the ADHD-RS-IV total score).  A total of 300 subjects (100 subjects in each of 
the three treatment groups) will be randomized to account for an anticipated 27.9% of 
randomized subjects not completing the study. 
7.10 Interim Analysis 
No interim analysis will be performed 
7.11 Pharmacokinetic Analyses 
Plasma concentrations for viloxazine (and 5-hydroxy-viloxazine glucuronide, if applicable) 
will be provided. 
 
    Population PK data analysis will be performed using 
nonlinear mixed-effects modeling program (NONMEM).  The structural model for 
viloxazine (and 5-hydroxy-viloxazine glucuronide, if applicable) may include data from 
studies in which sampling was more intensive than in the present study.  Inclusion of 
covariates in the pharmacokinetic model will be accomplished through a systematic 
process.  For each NONMEM run, covariate graphics will be examined for relationships 
between covariates and the post hoc etas.  Covariates of interest will include (but not be 
limited to) age, gender, body size, etc. Population PK analyses will be reported separately 
from the clinical study report. 
7.12 Pharmacogenomic Analysis 
If PGx testing is performed, individual data will be presented as a listing and summaries 
will be tabulated using descriptive statistics. 
 Reda
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 42 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
7.13 Safety Analysis 
Safety analysis as described below will be conducted on the Safety Population. Safety 
data that will be evaluated include concomitant medications, AEs, clinical laboratory 
results, vital signs, ECGs, and findings from the physical examinations.  Suicidal ideation 
and suicidal behavior will be measured by C-SSRS. 
The incidence rate of AEs will be calculated by treatment group for each System Organ 
Class (SOC) and Preferred Term (PT).  The severity of the AEs and the relationship to 
SM will be summarized by treatment group for each SOC and PT. 
AEs will be summarized using discrete summaries at the subject and event level by 
System Organ Class and Preferred Term, and by severity and relationship separately for 
each treatment group.  Verbatim description and Medical Dictionary for Regulatory 
Activities (MedDRA) SOCs and PTs for all AEs will be contained in the subject data 
listings. 
Clinical laboratory values will be summarized by visit by treatment group using descriptive 
statistics for hematology and biochemistry.  For quantitative laboratory parameters, both 
actual values and change from Screening values will be summarized. 
Vital signs will be summarized by visit by treatment group using descriptive statistics.  Both 
actual values and change from baseline will be summarized. 
ECG results will be summarized by visit by treatment group using descriptive statistics (for 
quantitative ECG parameters) and frequency tables (for qualitative ECG parameters, 
including the overall ECG finding). 
C-SSRS outcomes will be summarized using number and percent of subjects by 
categories for suicidal ideation only, suicidal behavior only and suicidality (ideation and 
behavior combined). The summary will be presented by treatment groups. 
8 
DOCUMENTATION 
8.1 
Adherence to the Protocol 
The Investigator agrees, when signing the protocol, to adhere to the instructions and 
procedures described within and to the principles of ICH GCP as well as all governing 
local regulations and principles for medical research. 
The protocol, ICF/IAF, and appropriate related documents must be reviewed and 
approved by an IRB constituted and functioning in accordance with ICH E6 and any local 
regulations. Documentation of IRB compliance with the ICH and any local regulations 
regarding constitution and review conduct will be provided to the Sponsor. 
A signed letter of study approval from the IRB must be sent to the Investigator with a copy 
to the Sponsor prior to study start and the release of SM to the site by the Sponsor or its 
designee.  If the IRB decides to suspend or terminate the study, the Investigator will 
immediately send the notice of study suspension or termination by the IRB to the Sponsor. 
8.2 
Changes to the Protocol 
Changes to the protocol will not be made without written approval from the Sponsor. 
Any change to the protocol requires a written protocol amendment or administrative 
change that must be approved by the Sponsor before implementation.  Amendments 
specifically affecting the safety of subjects, the scope of the investigation, or the scientific 
quality of the study require additional approval by the applicable IRB, and in some cases, 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 43 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
filings to the regulatory authority.  These requirements should in no way prevent any 
immediate action from being taken by the Investigator, or by the Sponsor, in the interest 
of preserving the safety of all subjects included in the study.  If an immediate change to 
the protocol is felt by the Investigator to be necessary for safety reasons, the Medical 
Monitor, and IRB must be notified promptly. 
Changes to the protocol which are administrative in nature do not require formal protocol 
amendments or IRB approval, but the IRB must be kept informed of such changes.  In 
these cases, the Sponsor or CRO will send a letter to the IRB detailing such changes. 
8.3 
Data Quality Assurance 
This study will be organized, performed, and reported in compliance with the protocol, 
standard operating procedures (SOPs), working practice documents, and applicable 
regulations and guidelines.  Site visit audits may be made periodically by the Sponsor’s 
Quality Assurance team or qualified designee, which is an independent function from the 
study conduct team. 
8.3.1 Data Collection 
The primary source document will be the subject’s medical record.  If separate research 
records are maintained by the Investigator(s), both the medical record and the research 
record will be considered the source documents for the purposes of monitoring and 
auditing the study. 
Electronic data collection techniques will be used to collect data directly from the study 
sites using eCRFs.  The electronic data will be stored centrally in a fully validated clinical 
database. 
Data recorded on source documents will be transcribed into the eCRFs in accordance with 
the eCRF Completion Instructions that are provided to the study sites.  The Investigator is 
responsible for ensuring that all sections of each eCRF are completed correctly, and that 
entries can be verified against source documents.  The eCRFs will be monitored for 
completeness and accuracy against the source documents by the CRA(s) on a regular 
basis.  Inconsistencies between the eCRFs and source documents will be resolved in 
accordance with the principles of GCP. 
8.3.2 Clinical Data Management 
Data from eCRFs and other external data (e.g., laboratory data) will be entered into or 
merged with a clinical database as specified in the data management plan.  Quality control 
and data validation procedures will be applied to ensure the validity and accuracy of the 
clinical database.   
8.3.3 Database Quality Assurance 
In accordance with the vendor’s procedures, the clinical database will be reviewed and 
checked for omissions, apparent errors, and values requiring further clarification using 
computerized and manual procedures.  The procedure for handling missing data will be 
addressed in the SAP.  Data queries requiring clarification will be documented and 
returned to the study site for resolution.  Only authorized personnel will make corrections 
to the clinical database, and all corrections will be documented in an audit trail.  
8.3.4 Bioanalytical Sample Handling 
Viloxazine and 5-hydroxy-viloxazine glucuronide concentrations in plasma samples will be 
determined using a validated chromatographic method. Viloxazine concentrations will be 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 44 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
reported as viloxazine free base. Details on the analytical methodology, the method of 
validation, and the analytical within-study quality control procedures will be included in the 
clinical study report for this protocol.  
8.4 
Retention of Records 
The Investigator has the responsibility to retain all study “essential documents”, as 
described in ICH E6 for at least two years after approval of a marketing application or after 
formal discontinuation of the clinical program.  Essential documents include but not limited 
to the protocol, copies of paper CRFs or eCRFs, source documents, laboratory test 
results, SM inventory records, Investigator's Brochure, regulatory agency registration 
documents (e.g., FDA form 1572, ICFs, and IRB correspondence).  The Investigator must 
obtain written permission from Supernus prior to the destruction of any study document.  
8.5 
Auditing Procedures 
In addition to the routine monitoring procedures, the Sponsor’s Corporate Quality 
Assurance department or qualified designee may conduct audits of clinical research 
activities in accordance with the Sponsor’s written SOPs to evaluate compliance with the 
principles of ICH GCP and all applicable local regulations.  A government regulatory 
authority may also wish to conduct an inspection (during the study or after its completion).  
If an inspection is requested by a regulatory authority, the Investigator must inform the 
Sponsor and the CRO immediately that this request has been made. 
These records must be made available at reasonable times for inspection and duplication, 
if required, by a properly authorized representative of the US FDA in accordance with the 
US 21 Code of Federal Regulation (CFR) 312.68 or other national or foreign regulatory 
authorities in accordance with regulatory requirements. 
8.6 
Publication of Results 
Any presentation or publication of data collected as a direct or indirect result of this trial 
will be considered as a joint publication by the Investigator(s) and the appropriate 
personnel at the Sponsor’s site.  Authorship will be determined by mutual agreement.  All 
manuscripts, abstracts or other modes of presentation arising from the results of the study 
must be reviewed and approved in writing by the Sponsor, prior to submission for 
publication or presentation.  No publication or presentation with respect to the study shall 
be made until any Sponsor comments on the proposed publication or presentation have 
been addressed to the Sponsor’s satisfaction. 
The detailed obligations regarding the publication of any data, material results, or other 
information, generated or created in relation to the study shall be outlined in the agreement 
between each Investigator and the Sponsor or designee. 
8.7 
Financing and Insurance 
Financing and Insurance information will be set forth in a separate document between the 
Investigator and Sponsor (provided by the Sponsor or designee). 
8.8 
Disclosure and Confidentiality 
The contents of this protocol, any amendments, and results obtained during the course of 
this study will be kept confidential by the Investigator, the Investigator’s staff, and the IRB 
and will not be disclosed in whole or in part to others or used for any purpose other than 
reviewing or performing the study without the written consent of the Sponsor.  No data 
collected as part of this study will appear in any written work, including publications, 
without the written consent of Sponsor. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 45 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
All persons assisting in the performance of this study must be bound by the obligations of 
confidentiality and non-use set forth in the Confidentiality Agreement between the 
Investigator and Sponsor. 
8.9 
Discontinuation of Study 
The Sponsor reserves the right to discontinue the study for medical or administrative 
reasons at any time.  The Investigator will be reimbursed for reasonable expenses 
covering subjects, use of live-in facilities, laboratory tests, and other professional fees.  
The Investigator will refund the excess of payments made in advance. 
The Investigator reserves the right to discontinue the study should his/her judgment so 
dictate.  The Investigator will notify the IRB in case of study discontinuation.  Study records 
must be retained as noted above. 
9 
ETHICS 
9.1 
Institutional Review Boards 
The IRB that approved this study and the approval letters will be included in the clinical 
study report for this protocol. 
The protocol, any protocol amendments, and the ICF/IAF will be reviewed and approved 
by the appropriate IRB before subjects are enrolled.  The Investigators or Sponsor will 
submit, depending on local regulations, periodic reports and inform the IRB of any 
reportable AEs per ICH guidelines and local IRB standards of practice.  
9.2 
Ethical Conduct of the Study 
This study will be conducted in accordance with SOPs from both the Sponsor and the 
CRO.  These SOPs are designed to ensure adherence to GCP guidelines as required by: 
 
Declaration of Helsinki, 1964 (“Recommendations Guiding Physicians in 
Biomedical Research Involving Human Patients”), and all its accepted 
amendments to date concerning medical research in humans. 
 
ICH Guideline for GCP (Committee for Proprietary Medicinal 
Products/ICH/135/95) of the European Agency for the Evaluation of Medicinal 
Products, Committee for Proprietary Medicinal Products, ICH of Pharmaceuticals 
for Human Use. 
 
United States (US) CFR dealing with clinical studies (21 CFR, including parts 50 
and 56 concerning Patient Informed Consent/Assent and IRB regulations). 
 
Local, national legal guidelines. 
9.3 
Investigators and Study Personnel 
This study will be conducted by qualified Investigators under the sponsorship of Supernus 
Pharmaceuticals, Inc. (Sponsor) at approximately 25 study sites in the US. 
Contact persons at the Sponsor and the CROs are listed in the reference binder provided 
to each investigational site.  The study will be monitored by qualified personnel from the 
Sponsor or their designees, such as the CROs, for their respective sites.  Medical writing, 
data management, and statistical analyses will be performed by the CROs.  Laboratory 
tests will be conducted by a central laboratory as designated in the reference binder.  
The study will be monitored by qualified personnel from Supernus.  Data management 
and statistical analyses will be the responsibility of the CRO data management and 
biostatistics groups.  

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 46 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
9.4 
Subject Information and Consent 
The Investigator (or designee) will inform the caregiver and subject of all aspects 
pertaining to the subject’s participation in the study and will provide oral and written 
information describing the nature and duration of the study, the procedures involved, the 
expected duration, the potential risks and benefits involved, and any potential discomfort. 
The process for obtaining informed consent will be in accordance with all applicable 
regulatory requirements.  The Investigator (or designee) and subject must sign and date 
the ICF/IAF before the subject can participate in the study.  The caregiver/subject will be 
given a copy of the signed and dated ICF/IAF and the original will be retained in the 
investigational site study records. 
The decision regarding subject participation in the study is entirely voluntary.  The 
Investigator (or designee) must emphasize to the subject that consent, regarding study 
participation, may be withdrawn at any time without penalty or loss of benefits to which the 
subject is otherwise entitled. 
If the ICF/IAF is amended during the study, the Investigator must follow all applicable 
regulatory requirements pertaining to approval of the amended ICF/IAF by the IRB and 
use the amended ICF/IAF (including ongoing subjects). 
10 REFERENCES 
Abidin, R. R. (1995). Parenting Stress Index, Third Edition: Professional Manual. Odessa, 
FL: Psychological Assessment Resources, Inc. 
Becker A, Roessner V, Breuer D, Dopfner M, Rothenberger A.  Relationship between 
quality of life and psychopathological profile: data from an observational study in children 
with ADHD. Eur Child Adolesc Psychiatry (2011); 20(2):267-275. 
DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-5 for Children and 
Adolescents: Checklists, Norms, and Clinical Interpretation. New York, NY: The Guilford 
Press. 2016. 
Epstein JN, Weiss MD.  Assessing Treatment Outcomes in Attention-Deficit/Hyperactivity 
Disorder: A Narrative Review. Prim Care Companion CNS Disord. 2012; 14(6): 
PCC.11r01336. 
Gajria K, Kivote V, Sikirica V, Reilly K, Kosinski M, Erder MH. (2015) Validation of the 
Weiss Functional Impairment 
Rating Scale – Parent Report Form in attention 
deficit/hyperactivity disorder. European Neuropsychopharmacology, Volume 24 , S711 - 
S712. 
Guy, W. (1976). “Clinical Global Impression (CGI). Early Clinical Drug Evaluation Unit 
(ECDEU) Assessment 
Manual for Psychopharmacology”.  Rockville, MD: U.S. 
Department of Health, Education, and Welfare; Public Health Service, Alcohol, Drug 
Abuse, and Mental Health Administration; 
National Institute of Mental Health; 
Psychopharmacology Research Branch; Division of Extramural Research Programs. pp. 
218–222. 
Sparrow EP Essentials of Conners Behavior Assessments. Hoboken, NJ: John Wiley & 
Sons, Inc. 2010. 
SPN-812V-ER Investigator's Brochure v5.0, 2017. 
Thompson T, Lloyd A, Joseph A, Weiss M.  The Weiss Functional Impairment Rating 
Scale-Parent Form for assessing ADHD: evaluating diagnostic accuracy and determining 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
812P303 
Version 4.0 
Page 47 of 47 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any 
viewing or disclosure of such information that is not authorized in writing by the Sponsor is strictly prohibited.  
Such information may be used solely for the purpose of reviewing or performing this study. 
optimal 
thresholds using ROC analysis. Qual Life Res. (2017); Feb 20. doi: 
10.1007/s11136-017-1514-8. [Epub ahead of print].   
Westfall, Peter H., Tobias, Randall D., and Wolfinger, Russell D., (1999). Multiple 
Comparisons and Multiples Tests Using SAS®, Cary, NC: SAS Institute Inc. 
Wiener J, Biondic D, Grimbos T, Herbert M. Parenting Stress of Parents of Adolescents 
with Attention-Deficit Hyperactivity Disorder. Journal of Abnormal Child Psychology 
(2016); 44(3):561-574. 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 1 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
SUMMARY OF CHANGES 
INCLUDED IN THE PROTOCOL AMENDMENT OF: 
 
812P303 
Evaluation of SPN-812 ER 200 and 400 mg Efficacy and Safety in Children with ADHD - A 
Double-Blind, Placebo-Controlled, Pivotal Trial 
 
Current Protocol 
Version 3.0 
07 September 2017 
Amended Protocol 
Version 4.0 
17 September 2018 
 
IND # 108,864 
SUMMARY OF REVISIONS 
This amendment incorporates the following protocol revisions: 
 
Updates and clarifications to the secondary and exploratory objectives and endpoints  
 
Revisions and clarifications to the Statistical Methods sections (based on the revised Statistical 
Analysis Plan dated 17 September 2018) 
 
Addition of 5-hydroxy-viloxazine glucuronide to PK assessments  
 
Expanded concomitant medications prohibitions to include CYP1A2 substrates 
 
Other minor editorial and administrative changes to improve clarity and correct errors 
 
RATIONALE 
1. The 812P303 Statistical Analysis Plan (SAP) was revised and updated based on the FDA review 
comments (FDA Advice Letter dated 19 July 2018, Ref ID 4294123).  The protocol was amended to 
reflect the changes in the revised SAP, including the following updates: 
 The secondary objectives and endpoints were updated and clarified to identify those considered 
“key” for data analysis and interpretation purposes. The exploratory objectives and endpoints 
were updated accordingly. 
 Methods for handling missing data and for conducting the sensitivity analyses were revised (e.g., 
the LOCF method will no longer be used).  
 Clarifications were made to the definitions of the analysis populations and to the subject 
disposition categories. 
 The section on the primary endpoint analysis was updated to include a fixed effect of age group 
and to provide new details with respect to the analysis of covariance (per FDA suggestion).  
 The Secondary Efficacy Analyses Sections were expanded to include descriptions of the key 
secondary analyses, additional secondary analyses, and subgroup analyses.  The Exploratory 
Analyses section was also added for the newly identified exploratory efficacy variables. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 2 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
2. 
 
 
 
3. 
 
 
 
 
 
    
4. Some information was reorganized or slightly revised to provide clarifications, describe study 
procedures in a greater detail, and for consistency with the SAP.  Section numbers have been 
reformatted throughout the protocol as needed to clarify the content and to incorporate new 
information. 
 
Detailed Listing of Revisions 
Detailed modifications of the protocol text are indicated by strikethrough (for deletions) and bold (for 
additions). 
# 
Global Changes 
1 
Throughout the amended protocol, the protocol version and version date are updated to Version 4.0 and 
17 September 2018 respectively. 
2 
The Table of Contents is updated to reflect current document pagination. 
3 
Section numbers have been reformatted to reflect information that was added, deleted, or relocated. 
4 
ADHD-RS-V and DSM-V have been replaced with ADHD-RS-5 and DSM-5, respectively, to reflect the DSM-5 
nomenclature 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
5 
Protocol Approval Page, p.3 
 
 
 
 
 
 
 
 
 
 
 
Protocol Approval Page, p.3 
 
 
 
 
 
 
 
 
 
 
 
Administrative 
change 
 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 3 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
 
 
 
Approver: 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
6 
Clinical Protocol Synopsis, Objective, 
Secondary, p.4 
• To assess the effect of SPN-812 ER as 
assessed by: 
o Conners 3rd edition (Conners 3) – 
parent, self (ages 8-11) 
o 30% Responder rate (Attention 
Deficit/Hyperactivity Disorder Rating 
Scale V [ADHD-RS-V] Total Score) 
o Hyperactivity/Impulsivity and 
Inattention subscales of ADHD-RS-V 
o Weiss Functional Impairment Rating 
Scale – Parent report (WFIRS-P) 
o Parenting Stress Index, Fourth Edition, 
Short Form (PSI-4-SF)  
o Clinical Global Impression - Severity of 
Illness and Improvement (CGI-S/I) 
Scale  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Protocol Synopsis, Objectives, p.4 
Key Secondary 
• To assess evaluate the effect of SPN-812 
ER compared to placebo as assessed by: 
o Clinical Global Impression – 
Improvement (CGI-I) scale 
o Conners 3rd edition (Conners 3) – 
parent, self (ages 8 11) composite T-
score 
o 30% Responder rate (Attention 
Deficit/Hyperactivity Disorder Rating 
Scale V [ADHD RS V] Total Score) 
o Hyperactivity/Impulsivity and 
Inattention subscales of ADHD RS V 
o Weiss Functional Impairment Rating 
Scale – Parent report (WFIRS-P) 
o Parenting Stress Index, Fourth Edition, 
Short Form (PSI 4 SF)  
o Clinical Global Impression  Severity of 
Illness and Improvement (CGI S/I) Scale  
Additional Secondary 
• To evaluate the effect of SPN-812 ER 
compared to placebo as assessed by: 
o 50% Responder rate based on the 
ADHD-RS-5 Total score 
o Parenting Stress Index, Fourth Edition, 
Short Form (PSI-4-SF) 
o ADHD-RS-5 Inattention and 
Hyperactivity/Impulsivity subscale 
scores 
o Conners 3 – Self, composite T-score 
(for ages 8-11 years) 
Update to 
secondary 
objectives and 
endpoints 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 4 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
 
• To evaluate the safety and tolerability of 
SPN-812 ER in children with ADHD 
Safety 
• To evaluate the safety and tolerability of 
SPN-812 ER in children with ADHD 
7 
Clinical Protocol Synopsis, Objective, 
Exploratory, p.4 
n/a 
Clinical Protocol Synopsis, Objectives, 
Exploratory, p.4 
 
 
 
 
 
 
 
 
 
Update to 
exploratory 
objectives and 
endpoints 
8 
Clinical Protocol Synopsis, Objective, 
Exploratory, p.4 
 
 
 
Clinical Protocol Synopsis, Objectives, 
Exploratory, p.4 
  
 
 
 
 
 
 
 
Assessment of 
viloxazine 
metabolite 
9 
Clinical Protocol Synopsis, Endpoints, p.5 
 
 
 
 
 
 
 
 
 
Clinical Protocol Synopsis, Endpoints, p.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Update to 
secondary 
objectives and 
endpoints 
 
 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 5 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
10 
Clinical Protocol Synopsis, Endpoints, p.5 
 
 
Clinical Protocol Synopsis, Endpoints, p.6 
 
 
 
 
 
 
 
 
 
Update to 
exploratory 
objectives and 
endpoints 
11 
Clinical Protocol Synopsis, Analysis 
Populations, p.6 
 
 
 
• The ITT population for efficacy will 
include all randomized subjects who took 
at least one dose of study medication, and 
had a Baseline and at least one post-
Baseline assessment of ADHD-RS-V. 
 
 
• The Per Protocol (PP) population 
consists of all subjects in the ITT 
population with no missing visits or ADHD-
RS-V assessments and no major protocol 
violations. 
 
 
• The Safety Population consists of all 
subjects who receive at least one dose of 
SM. 
 
 
• The PK population will include all 
subjects in the safety population with ≥1 
non-below-the limit-of-quantitation PK 
sample drawn. 
Clinical Protocol Synopsis, Analysis 
Populations, p.6 
• The Randomized population will include 
all enrolled subjects who had a baseline 
visit and are randomized via the IWRS. 
• The ITT population for efficacy will 
include all randomized subjects who took 
at least one dose of study medication, and 
had a Baseline and at least one post-
Baseline randomization ADHD-RS-5 
assessment of ADHD RS V. Subjects will be 
analyzed according to the treatment to 
which they were randomized. 
• The Per Protocol (PP) population consists 
of all subjects in the ITT population who 
completed all 10 visits with no missing 
visits or ADHD-RS-V5 assessments and no 
major protocol violations. Subjects will be 
analyzed according to the treatment they 
actually received. 
• The Safety Population consists of all 
subjects randomized into the study who 
receive at least one dose of SM. Subjects 
will be analyzed according to the 
treatment they actually received. 
• The PK population will include all subjects 
in the safety population with ≥1 non-below 
the limit of quantitation PK sample drawn  
that is not below the Lower Limit of 
Quantitation (LLOQ). 
Updated for 
consistency 
with revised 
SAP 
12 
Clinical Protocol Synopsis, Handling of 
Missing Data, p.6 
For primary efficacy analysis, missing data 
will be assumed as Missing at Random 
(MAR) and will be handled using Mixed 
Models Repeated Measures (MMRM) 
technique according to the MMRM 
Clinical Protocol Synopsis, Handling of 
Missing Data, p.6 
For With respect to the primary efficacy 
analysis, missing data ADHD-RS-5 Total 
Scores will be assumed as to be Mmissing 
at Rrandom (MAR) and will be handled 
using a Mixed Models for Repeated 
LOCF method 
no longer used 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 6 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
paradigm.  For secondary and first 
sensitivity analyses, missing data will be 
imputed using the last observation carried 
forward (LOCF) method. 
Measures (MMRM) technique according to 
the MMRM paradigm method in SAS.  For 
secondary and first sensitivity analyses, 
missing data will be imputed using the last 
observation carried forward (LOCF) 
method. The sensitivity analysis for the 
primary endpoint will be performed by 
assuming that missing ADHD-RS-5 Total 
Scores are missing not at random (MNAR). 
For analysis of secondary endpoints, 
missing values will be assumed as MAR. 
13 
Clinical Protocol Synopsis, Statistical 
Methods, p.6 
In general, continuous variables will be 
summarized with standard descriptive 
statistics including number of subjects (n), 
means, standard deviations, medians, 
minimum, and maximum. Categorical 
variables will be summarized with 
frequencies and percentages. 
Clinical Protocol Synopsis, Statistical 
Methods, p.7 
In general, continuous variables will be 
summarized with standard descriptive 
statistics including number of subjects (n), 
means, standard deviations, medians, 
minimum, and maximum. Categorical 
variables will be summarized with 
frequencies and percentages. All 
tabulations of analysis results will include 
summaries for the following three 
treatments: SPN-812 ER 400 mg, SPN-812 
ER 200 mg, and placebo. 
Where appropriate, variables will be 
summarized descriptively (frequency 
count and percent for categorical 
variables, and number of subjects (n), 
mean, standard deviation (SD), median, 
minimum, and maximum for continuous 
variables). 
Categorical variables will be analyzed 
using categorical response methods such 
as Pearson’s Chi-square test.  If expected 
frequencies are less than 5 in a given cell, 
then exact testing techniques will be used. 
Descriptive statistics will be presented for 
demographics, data from the clinical 
laboratory tests, vital signs, weight, ECGs, 
and C-SSRS. 
Updated for 
consistency 
with revised 
SAP 
14 
Clinical Protocol Synopsis, Statistical 
Methods, Efficacy Analyses, p.6 
Primary: The primary endpoint is change 
from baseline in ADHD-RS-V Total Score 
and the primary analysis, based on the ITT 
population, will be performed using a 
longitudinal MMRM and a restricted 
Clinical Protocol Synopsis, Statistical 
Methods, Efficacy Analyses, p.7 
Primary: The primary endpoint is change 
from baseline in ADHD RS V Total Score 
and the primary analysis, based on the ITT 
population, will be performed using a 
longitudinal MMRM and a restricted 
Updated for 
consistency 
with revised 
SAP, and LOCF 
no longer used 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 7 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
maximum likelihood (REML) approach. An 
unstructured (co)variance structure will be 
used to model the within-subject errors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Each of the active treatment groups (SPN-
812 ER 200 and 400 mg) will be compared 
with placebo. The p-values, Least Squares 
(LS) of treatment means, differences 
between the LS treatment means and 
placebo, and 95% confidence intervals for 
the treatment differences will be 
computed. 
 
 
 
 
 
 
 
 
 
Secondary: The CFB to EOS for continuous 
key secondary and additional endpoints 
will be analyzed using ANCOVA or ANOVA 
maximum likelihood (REML) approach. An 
unstructured (co)variance structure will be 
used to model the within subject errors. 
The primary efficacy variable, change from 
baseline in ADHD-RS-5 Total Score to 
Week 8 (EOS), will be analyzed using a 
Mixed Model for Repeated Measures 
(MMRM), which assumes that missing 
data are missing at random (MAR). The 
model will include fixed effect terms for 
baseline ADHD-RS-5 Total Score, age 
group, treatment, visit, and treatment-by-
visit interaction as independent variables. 
The model parameters will be estimated 
using restricted maximum likelihood 
method with unstructured variance-
covariance matrix and Kenward-Roger 
approximation to estimate denominator 
degrees of freedom. In case there is a 
convergence problem in the MMRM 
model with the unstructured variance 
covariance matrix, the first (co)variance 
structure which does not have 
convergence problem will be used for the 
analysis from the following ordered list: 1) 
Toeplitz, 2) Autoregressive of order 1, and 
3) Compound symmetry. 
The adjusted mean (LS Mean) of CFB to 
EOS for ADHD-RS-5 Total Score for each 
treatment group (Placebo, SPN-812 ER 200 
mg and SPN-812 ER 400 mg) will be 
presented, along with the corresponding 
standard error. Each of the active 
treatment groups (SPN-812 ER 200 and 400 
mg) will be compared with placebo. The p-
values, Least Squares (LS) of treatment 
means, differences between the LS 
treatment means and placebo, and 95% 
confidence intervals for the treatment 
differences will be computed. 
Sensitivity analysis: The sensitivity analysis 
assumes that missing ADHD-RS-5 Total 
Scores are missing not at random (MNAR). 
Placebo-based multiple imputation will be 
used to fill in missing values. 
Secondary: The CFB to EOS for continuous 
key secondary and additional endpoints will 
be analyzed using ANCOVA or ANOVA as 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 8 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
as appropriate based on the ITT 
population with LOCF.  The mean of each 
treatment group will be compared with 
the mean of the placebo group.  For 
responder analyses, the proportion of 
each active treatment group will be 
compared with the proportion of the 
placebo group. 
appropriate based on the ITT population 
with LOCF.  The mean of each treatment 
group will be compared with the mean of 
the placebo group.  For responder analyses, 
the proportion of each active treatment 
group will be compared with the 
proportion of the placebo group. The 
secondary analyses will be based on the 
ITT population with missing values 
imputed using multiple imputation 
assuming MAR. All secondary analyses will 
be analyzed using ANCOVA (except CGI 
which uses ANOVA on the absolute value 
of CGI-I at Week 8 (EOS) on the change 
from baseline at Week 8 (EOS) with 
treatment and baseline as fixed effect.  
15 
Clinical Protocol Synopsis, Statistical 
Methods, Safety Analyses, p.6 
Descriptive statistics will be presented for 
demographics, data from the clinical 
laboratory tests, vital signs, weight, ECGs, 
and physical examinations. 
Clinical Protocol Synopsis, Statistical 
Methods, Safety Analyses, p.7 
(Deleted) Descriptive statistics will be 
presented for demographics, data from the 
clinical laboratory tests, vital signs, weight, 
ECGs, and physical examinations. 
Statement 
moved for 
clarification 
purposes 
16 
Clinical Protocol Synopsis, Parmacokinetic 
and Pharmacogenomic Methods, 
Sampling, p.6  
A maximum of five blood samples will be 
collected at one or more of Visits 3-10. 
Clinical Protocol Synopsis, Pharmacokinetic 
and Pharmacogenomic Methods, Sampling, 
p.8  
For PK analysis, aA maximum of five blood 
samples will be collected at one or more of 
Visits 3-10. For PGx analysis, a single blood 
sample will be collected at screening. 
Clarification 
17 
Clinical Protocol Synopsis Parmacokinetic 
and Pharmacogenomic Methods, 
Bioanalytical Analysis, p.6  
Viloxazine concentrations in plasma will 
be determined for all treatments using a 
validated achiral chromatographic 
method.  Concentrations will be reported 
as viloxazine free base. 
Clinical Protocol Synopsis Pharmacokinetic 
and Pharmacogenomic Methods, 
Bioanalytical Analysis, p.8  
Viloxazine concentrations and 5-hydroxy-
viloxazine glucuronide concentrations in 
plasma will be determined for all 
treatments using a validated achiral 
chromatographic method.  Viloxazine 
concentrations will be reported as 
viloxazine free base. 
Assessment of 
viloxazine 
metabolite 
18 
Clinical Protocol Synopsis, Parmacokinetic 
and Pharmacogenomic Methods, 
Pharmacokinetic Analysis, p.6  
n/a 
Clinical Protocol Synopsis, Pharmacokinetic 
and Pharmacogenomic Methods, 
Pharmacokinetic Analysis, p.8  
(Added) Plasma concentrations for 
viloxazine (and 5-hydroxy-viloxazine 
glucuronide, if applicable) will be 
provided.  
Assessment of 
viloxazine 
metabolite 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 9 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
19 
Clinical Protocol Synopsis, Parmacokinetic 
and Pharmacogenomic Methods, 
Pharmacokinetic Analysis, p.6  
The analyses’ report will be a stand-alone 
document. 
Clinical Protocol Synopsis, Pharmacokinetic 
and Pharmacogenomic Methods, 
Pharmacokinetic Analysis, p.8  
The analyses’ report will be a stand alone 
document. Population PK analyses will be 
reported separately from the clinical study 
report. 
Clarification 
20 
Clinical Protocol Synopsis, Parmacokinetic 
and Pharmacogenomic Methods, 
Pharmacogenomics Analysis, p.7 
 
 
  
Clinical Protocol Synopsis, Pharmacokinetic 
and Pharmacogenomic Methods, 
Pharmacogenomics Analysis, p.8 
The If a given subject’s PK data warrant 
evaluation of PGx, 
 
 
 
  
Clarification 
21 
Clinical Protocol Synopsis, Parmacokinetic 
and Pharmacogenomic Methods, 
Pharmacogenomics Analysis, p.7 
The PGx report may be a stand-alone 
document. 
Clinical Protocol Synopsis, Pharmacokinetic 
and Pharmacogenomic Methods, 
Pharmacogenomics Analysis, p.8 
The PGx report may be a stand alone 
document. If PGx testing is performed, 
individual data will be presented as a 
listing and summaries will be tabulated 
using descriptive statistics. 
Clarification 
22 
List of Abbreviations, p.12 
ADHD-RS-IV/V   ADHD Rating Scale- IV/V 
DSM-5  Diagnostic and Statistical Manual 
of Mental Disorders-V 
ET          Early Termination 
 
LOCF     Last Observation Carried Forward 
MMRM  Mixed Models Repeated 
Measures 
List of Abbreviations, p.13 
ADHD-RS-IV/V5   ADHD Rating Scale- IV/V5 
DSM-5      Diagnostic and Statistical Manual 
of Mental Disorders-V5 
ET              Early Termination 
LLOQ        Lower Limit of Quantitation 
LOCF        Last Observation Carried Forward 
MMRM   Mixed Models for Repeated 
Measures 
MNAR     Missing Not At Random 
Editorial 
change 
23 
1.2 Clinical Information, Phase 2 Studies, 
p.16 
Information and data from clinical studies 
are available in detail in the SPN-812 ER 
Investigator’s Brochure, version 5.0. 
1.2 Clinical Information, Phase 2 Studies, 
p.16 
Information and data from clinical studies 
are available in detail in the SPN-812 ER 
Investigator’s Brochure, version 5.0 6.0. 
Correction 
24 
2.2 Secondary Objectives, p.16 
 
 To assess the effect of SPN-812 ER 
compared to placebo as assessed by: 
o 
Conners 3rd edition – parent, self 
(ages 8-11) 
o 
30% Responder rate (ADHD-RS-V) 
2.2 Secondary Objectives, p.17 
Key Secondary 
 To assess evaluate the effect of SPN-812 
ER compared to placebo as assessed by: 
o 
Clinical Global Impression - 
Improvement (CGI-I) scale 
Update to 
secondary 
objectives and 
endpoints 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 10 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
o 
Hyperactivity/Impulsivity and 
Inattention subscales of ADHD-RS-V 
o 
Weiss Functional Impairment Rating 
Scale-Parent Report (WFIRS-P) 
o 
Parenting Stress Index, Fourth 
Edition, Short Form (PSI-4-SF) 
o 
Clinical Global Impression – Severity 
of illness and Improvement (CGI-
S/I) Scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 To evaluate the safety and tolerability of 
SPN-812 ER in 6-11 year-olds. 
o 
Conners 3rd edition (Conners 3)  – 
parent, self (ages 8 11) composite 
T-score 
o 
30% Responder rate (ADHD RS V) 
o 
Hyperactivity/Impulsivity and 
Inattention subscales of ADHD RS
V 
o 
Weiss Functional Impairment 
Rating Scale-Parent Report 
(WFIRS-P) 
o 
Parenting Stress Index, Fourth 
Edition, Short Form (PSI-4-SF) 
o 
Clinical Global Impression – 
Severity of illness and 
Improvement (CGI S/I) Scale 
(Added) Additional Secondary 
 To evaluate the effect of SPN-812 ER 
compared to placebo as assessed by: 
o 
50% Responder rate based on the 
ADHD-RS-5 Total score 
o 
Parenting Stress Index, Fourth 
Edition, Short Form (PSI-4-SF) 
o 
ADHD-RS-5 Inattention and 
Hyperactivity/Impulsivity 
subscale scores 
o 
Conners 3 – Self, composite T-
score (for ages 8-11 years) 
Safety 
 To evaluate the safety and tolerability of 
SPN-812 ER in 6 11 year olds children 
with ADHD. 
25 
2.3 Exploratory, p.16 
n/a 
2.3 Exploratory Objectives, p.18 
(Added) 

 
 
 
 
 
 
 
 
 
 
 
 
Update to 
exploratory 
objectives and 
endpoints 
26 
2.3 Exploratory, p.16 
 
 
 
2.3 Exploratory Objectives, p.18 
 
  
 
 
 
  
Assessment of 
viloxazine 
metabolite 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 11 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
 
 
 
 
 
27 
3.1 Overall Study Design and Plan, p.17 
This is a multicenter, randomized, double-
blind, placebo-controlled, 3-arm, parallel-
group study, to assess the efficacy and 
safety of SPN-812 ER as monotherapy for 
the treatment of children 6-11 years old 
with ADHD. 
Screening (Visit 1):  After administering 
the informed consent form (ICF) and 
informed assent form (IAF, if applicable), 
subjects will undergo initial screening 
evaluation including medical and 
psychiatric history, ECG, vital signs, 
physical examination, routine laboratory 
assessment, PGx testing, and urine drug 
screen. 
3.1 Overall Study Design and Plan, p.18 
This is a multicenter, randomized, double-
blind, placebo-controlled, 3-arm, parallel-
group study, to assess evaluate the efficacy 
and safety of SPN-812 ER as monotherapy 
for the treatment of children 6-11 years old 
with ADHD. 
Screening (Visit 1):  After administering the 
informed consent form (ICF) and informed 
assent form (IAF, if applicable), subjects will 
undergo initial screening evaluation 
including medical and psychiatric history, 
ECG, vital signs, physical examination, 
routine laboratory assessment, PGx testing 
sample collection, and urine drug screen. 
Editorial 
change 
28 
3.1 Overall Study Design and Plan, p.17 
An optional PK substudy will be conducted 
between visits 3 and 10, inclusive, to 
assess viloxazine PK characteristics in this 
pediatric population. 
3.1 Overall Study Design and Plan, p.19 
An optional PK substudy will be conducted 
between visits 3 and 10, inclusive, to assess 
viloxazine the PK characteristics of 
viloxazine (and its metabolite, 5-hydroxy-
viloxazine glucuronide, if applicable) in this 
pediatric population. 
Assessment of 
viloxazine 
metabolite 
29 
3.3.3 Exclusion Criteria, p.19 
1. Current diagnosis of major 
psychological disorders.  
3.3.3 Exclusion Criteria, p.20 
1. Current diagnosis of major psychological 
psychiatric disorders.  
Clarification 
30 
4.3 Method of Assigning Subjects to 
Treatment Group, p.20 
Treatment B: SPN-812 ER100 mg/day (2 x 
100 mg SPN-812 ER) 
Treatment C: SPN-812 ER 200 mg/day (4 x 
100 mg SPN-812 ER) 
4.3 Method of Assigning Subjects to 
Treatment Group, p.22 
Treatment B: SPN-812 ER100 200 mg/day 
(2 x 100 mg SPN-812 ER) 
Treatment C: SPN-812 ER 200 400 mg/day 
(4 x 100 mg SPN-812 ER) 
Correction 
31 
4.6 Concomitant Medications, p.22 
n/a 
4.6 Concomitant Medications, p.23 
(Added) Specific concomitant medication 
prohibitions include known CYP1A2 
substrates (e.g., theophylline, melatonin, 
olanzapine, duloxetine).   
New restriction 
on 
concomitant 
medications 
metabolized by 
CYP1A2 
32 
5.1.1 Visit 1 Screening (Day -28 to -1), p.24 
8. Collect blood samples for hematology, 
chemistry and pharmacogenomic testing 
5.1.1 Visit 1 Screening (Day -28 to -1), p.26 
8. Collect blood samples for hematology, 
chemistry and pharmacogenomic testing 
PGx 
Clarification 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 12 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
33 
5.1.5 Pharmacogenomic Sample 
Collection, p.25 
 
 
  
5.1.5 Pharmacogenomic Sample Collection, 
p.27 
The If a given subject’s PK data warrant 
evaluation of PGx, 
 
 
 
  
Clarification 
34 
5.1.5 Pharmacogenomic Sample 
Collection, p.25 
n/a 
5.1.5 Pharmacogenomic Sample Collection, 
p.27 
(Added) The DNA analysis will not be used 
for individual genetic characterization and 
the subject’s identity will be kept 
confidential. 
Clarification 
35 
6.1 Primary Efficacy  Variable, p.26 
 
The scale consists of 18 items that directly 
correspond to the 18 DSM-V symptoms 
and are further subdivided into two 
subscales: Hyperactivity/Impulsivity and 
Inattentiveness (DuPaul, 2016). 
6.1 Primary Efficacy  Variable, p.28 
6.1.1 ADHD-RS-5 
The scale consists of 18 items that directly 
correspond to the 18 DSM-V5 symptoms 
and are further subdivided into two 
subscales: Hyperactivity/Impulsivity and 
Inattentiveness Inattention (DuPaul, 2016). 
 
Editorial 
change 
36 
6.2 Key Secondary Efficacy Variables: , 
p.26 
 
a) Conners 3 
b) 30% Responder Rate (ADHD-RS-V Total 
Score) 
c) Hyperactivity/Impulsivity and 
Inattention subscales of ADHD-RS-V 
6.2 Key Secondary Efficacy Variables:, p.28 
The key secondary efficacy variables 
include: 
a) Conners 3 CGI-I 
b) 30% Responder Rate (ADHD RS V Total 
Score) Conners 3 – Parent, composite T-
score 
c) Hyperactivity/Impulsivity and Inattention 
subscales of ADHD RS V WFIRS-P average 
score 
Update to 
secondary 
objectives and 
endpoints 
37 
6.3 Additional Secondary Efficacy 
Variables, p. 26 
a) WFIRS-P 
b) PSI-4-SF 
c) CGI-S/I 
6.3 Additional secondary Efficacy variables 
will include:, p.28 
a) WFIRS P Proportion of responders with 
50% improvement in the ADHD-RS-5 
Total score (50% Responder rate) 
b) PSI-4-SF 
c) CGI S/I ADHD-RS-5 Inattention and 
Hyperactivity/Impulsivity subscale 
scores 
d) Conners 3 – Self, composite T-score (for 
ages 8-11 years) 
Update to 
secondary 
objectives and 
endpoints 
38 
Version 4.0, (Added) 6.2.1 Clinical Global Impression - Improvement, p.28 
The CGI scale was developed to provide a brief, stand-alone assessment of the 
clinician’s view of a subject’s global functioning prior to and after administration of a 
Editorial 
change 
(section moved 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 13 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
SM (Guy 1976).  The Clinical Global Impression – Severity of Illness (CGI-S) is a single 
item clinician rating of clinician’s assessment of the severity of the ADHD symptoms in 
relation to the clinician’s total experience with patients with ADHD.  The Clinical Global 
Impression – Improvement Scale (CGI-I) is an assessment of how much the patient’s 
illness has improved or worsened relative to a baseline state at the beginning of 
treatment. Both CGI-S and CGI-I are rated on a 7-point scale of 1 to 7 with 7 being 
“extremely ill” or “very much worse”, respectively.  Successful therapy is indicated by a 
lower overall score in subsequent testing.   
• CGI-S will be evaluated by the Investigator at Screening and Baseline on a 7-point 
scale with 1=Normal,    2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 
6=Severely ill, and 7=Extremely ill.    
• CGI-I, relative to the condition at baseline, will be evaluated by the Investigator at 
each post-baseline visit on a 7-point scale with 1=Very much improved, 2=Much 
improved, 3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, 
and 7=Very much worse. 
with no change 
to content) 
39 
6.4.2 Conners 3, p.26 
The Conners 3 scales will be administered 
at Visit 2 (Baseline) and at Visit 8 (EOS) 
according to subjects’ age as follows: 
6.2.2 Conners 3, p.29 
The Conners 3 scales will be administered 
at Visit 2 (Baseline) and at Visit Week 8 
(EOS) according to subjects’ age as follows: 
Correction 
40 
6.4.3 WFIRS-P, p.27 
The WFIRS instrument evaluates ADHD-
related functional impairment (Gajria, 
2015; Thompson, 2017). 
 
 
The scale has been validated in the ADHD 
population; the parent-based version 
completed by the parent/guardian of a 
child is used in this study and comprises 
50 items grouped into six domains: Family, 
School (learning and behavior), Life Skills, 
Child’s Self-Concept, Social Activities, and 
Risky Activities.   
6.2.3 WFIRS-P, p.29 
The Weiss Functional Impairment Rating 
Scale (WFIRS) instrument evaluates ADHD-
related functional impairment (Gajria, 
2015; Thompson, 2017). 
 
The scale has been validated in the ADHD 
population; the parent-based version 
(WFIRS-P) completed by the 
parent/guardian of a child is used in this 
study and comprises 50 items grouped into 
six domains: Family, School (learning and 
behavior), Life Skills, Child’s Self-Concept, 
Social Activities, and Risky Activities.   
Editorial 
change 
41 
6.4.4 PSI-4-SF, p.27 
The short form (PSI-4-SF) of the PSI-4 
consists of 36 items divided into three 
domains: parental stress, parent-child 
dysfunctional interaction, and difficult 
child.   
6.2.4 PSI-4-SF, p.30 
The short form (PSI-4-SF) of the PSI-4 
consists of 36 items divided into three 
domains: parental stress distress, parent-
child dysfunctional interaction, and difficult 
child.   
Editorial 
change 
42 
Version 3.0, (Deleted) 6.4.5 CGI-S/I, p.27 
The CGI scale was developed to provide a brief, stand alone assessment of the clinician’s 
view of a subject’s global functioning prior to and after administration of a SM (Guy 
1976).  The Clinical Global Impression  Severity of Illness (CGI S) is a single item clinician 
rating of clinician’s assessment of the severity of the ADHD symptoms in relation to the 
clinician’s total experience with patients with ADHD.  The Clinical Global Impression  
Improvement Scale (CGI I) is an assessment of how much the patient’s illness has 
Editorial 
change 
(section moved 
with no change 
to content) 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 14 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
improved or worsened relative to a baseline state at the beginning of treatment. Both 
CGI S and CGI I are rated on a 7 point scale of 1 to 7 with 7 being “extremely ill” or “very 
much worse”, respectively.  Successful therapy is indicated by a lower overall score in 
subsequent testing.   
• CGI S will be evaluated by the Investigator at Screening and Baseline on a 7 point scale 
with 1=Normal,    2=Borderline ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 
6=Severely ill, and 7=Extremely ill.    
• CGI I, relative to the condition at baseline, will be evaluated by the Investigator at each 
post baseline visit on a 7 point scale with 1=Very much improved, 2=Much improved, 
3=Minimally improved, 4=No change, 5=Minimally worse, 6=Much worse, and 7=Very 
much worse. 
43 
6.5 Safety Variables and Assessments, 
p.28 
 
 
 
 
Safety assessments will consist of 
monitoring of and recording of all 
concomitant medications and AEs, clinical 
laboratory tests, measurement of vital 
signs and 12-lead ECGs, suicidality 
monitoring, and the performance of 
physical examinations as detailed in the 
Schedule of Events and Assessments. 
6.3 Safety Variables and Assessments, p.30 
(Added) The safety variables for the study 
are AEs, clinical laboratory test results, 
vital signs, ECG results, and treatment-
emergent suicidal ideation. 
 
Safety assessments include will consist of 
monitoring, evaluation,  of and recording 
of all concomitant medications, and the 
evaluation of AEs, clinical laboratory test 
results, measurement of vital signs and 12-
lead ECGs, suicidality monitoring C-SSRS, 
and the performance of physical 
examinations as detailed in the Schedule of 
Events and Assessments. 
Clarification 
44 
Version 4.0 (Added) 6.7 Exploratory Variables, p.35 
Exploratory variables include: 
 
 
 
 
 
 
  
Update to 
secondary 
objectives and 
endpoints, and 
assessment of 
viloxazine 
metabolite 
45 
7.1 General Considerations, p.33 
All data analyses will be performed by the 
designated CRO after the study is 
completed and the database is released. 
Statistical programming and analyses will 
be performed. All data will be analyzed 
using SAS (SAS Institute, Inc., Version 9.2 
or later).  
 
 
7.1 General Considerations, p.36 
All data analyses will be performed by the 
designated CRO after the study is 
completed and the database is released.  
Statistical programming and analyses will 
be performed. All data will be analyzed 
using SAS (SAS Institute, Inc., Version 9.2 or 
later). All statistical analysis will be 
performed using SAS version 9.2 or higher 
by 
, which is the designated CRO
 
will be responsible for developing a 
Updated for 
consistency 
with revised 
SAP 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 15 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
 
 
 
In general, continuous variables will be 
summarized with standard descriptive 
statistics including number of subjects (n), 
means, standard deviations, medians, 
minimum, and maximum. Categorical 
variables will be summarized with 
frequencies and percentages. 
unique program for each TLF to create a 
TLF report and deliver to Supernus at the 
completion of the study. 
In general, continuous variables will be 
summarized with standard descriptive 
statistics including number of subjects (n), 
means, standard deviations, medians, 
minimum, and maximum. Categorical 
variables will be summarized with 
frequencies and percentages. 
All tabulations of analysis results will 
include summaries for the following three 
treatments: SPN-812 ER 400 mg, SPN-812 
ER 200 mg, and placebo. 
Where appropriate, variables will be 
summarized descriptively (frequency 
count and percent for categorical 
variables, and number of subjects (n), 
mean, standard deviation (SD), median, 
minimum, and maximum for continuous 
variables).  
46 
7.1 General Considerations, p.33 
When inferential analyses are conducted 
for continuous variables, they will 
primarily be based on parametric general 
linear models such as analysis of 
covariance or analysis of variance. 
For variables that do not meet the 
normality assumptions, nonparametric 
methods, such as the Wilcoxon rank-sum 
method, will be used. 
 
Categorical variables will be analyzed 
using categorical response methods such 
as Pearson’s Chi-square test.  If expected 
frequencies are too small for asymptotic 
assumptions, exact testing techniques will 
be used. 
 
Treatment effects for all efficacy variables 
will be evaluated based on a two- sided 
significance level of 0.05 and the 
interaction effects at 0.10. 
Subject characteristics are assumed to be 
comparable at the start of the study, as 
randomization is designed to ensure 
balance between the groups on the 
7.1 General Considerations, p.36 
(Deleted) When inferential analyses are 
conducted for continuous variables, they 
will primarily be based on parametric 
general linear models such as analysis of 
covariance or analysis of variance. 
(Deleted) For variables that do not meet 
the normality assumptions, nonparametric 
methods, such as the Wilcoxon rank sum 
method, will be used. 
 
Categorical variables will be analyzed using 
categorical response methods such as 
Pearson’s Chi-square test.  If expected 
frequencies are too small for asymptotic 
assumptions less than 5 in a given cell, 
then exact testing techniques will be used. 
 
(Deleted) Treatment effects for all efficacy 
variables will be evaluated based on a two  
sided significance level of 0.05 and the 
interaction effects at 0.10. 
(Deleted) Subject characteristics are 
assumed to be comparable at the start of 
the study, as randomization is designed to 
ensure balance between the groups on the 
Updated for 
consistency 
with revised 
SAP 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 16 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
baseline characteristics, so no formal 
statistical group comparisons will be 
conducted on the subject characteristics. 
baseline characteristics, so no formal 
statistical group comparisons will be 
conducted on the subject characteristics. 
47 
7.2 Handling of Missing Data, p.34 
For primary efficacy analysis, missing data 
will be assumed as Missing at Random 
(MAR) and will be handled using Mixed 
Models Repeated Measures (MMRM) 
technique according to the MMRM 
paradigm. Under MAR, the propensity for 
a data point to be missing is not related to 
the missing data, but is related to some of 
the observed data. For secondary and first 
sensitivity analyses, the last observation 
carried forward (LOCF) method of 
imputation will be used. The underlying 
assumption for using the LOCF method is 
based on the fact that 35% of subjects 
early terminated (ET) before completion 
of the Phase II 202 study as lost-to-follow-
up. It is assumed that majority of subject 
dropout in the Phase III trial will follow the 
same pattern and hence, the assumption 
of Missing Completely at Random (MCAR) 
can be applied and the LOCF imputation 
for missing data can be used. 
7.2 Handling of Missing Data, p.36 
For With respect to the primary efficacy 
analysis, missing data ADHD-RS-5 Total 
Scores will be assumed as to be Mmissing 
at Rrandom (MAR), that is, given the 
observed data, the reason for the missing 
data does not depend on the unseen data. 
and will be handled using The Mixed 
Models for Repeated Measures (MMRM) 
technique according to the MMRM 
paradigm method, implemented via SAS® 
PROC MIXED (SAS/STAT Software), will be 
used for handling missing ADHD-RS-5 Total 
Scores under MAR assumption. Under 
MAR, the propensity for a data point to be 
missing is not related to the missing data, 
but is related to some of the observed 
data. For secondary and first sensitivity 
analyses, the last observation carried 
forward (LOCF) method of imputation will 
be used. The underlying assumption for 
using the LOCF method is based on the fact 
that 35% of subjects early terminated (ET) 
before completion of the Phase II 202 study 
as lost to follow up. It is assumed that 
majority of subject dropout in the Phase III 
trial will follow the same pattern and 
hence, the assumption of Missing 
Completely at Random (MCAR) can be 
applied and the LOCF imputation for 
missing data can be used.  
(Added) 
The sensitivity analysis for the primary 
endpoint will be performed by assuming 
that missing ADHD-RS-5 Total Scores are 
missing not at random (MNAR) meaning 
that the probability that an observation is 
missing may depend on its underlying 
unobserved value.  
For analysis of secondary endpoints, 
missing values will be assumed as MAR.  
For safety analyses, missing dates for AEs 
and non-study medication use will be 
imputed as described in the SAP. Missing 
LOCF method 
no longer used 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 17 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
data for all other safety endpoints will not 
be imputed. 
48 
7.3 Analysis Populations, p.34 
 
 
 
 The Intent-to-Treat (ITT) population for 
efficacy will include all randomized 
subjects who took at least one dose of 
study medication and had a Baseline 
and ≥1 post-Baseline ADHD-RS-V 
assessment. Subjects will be analyzed 
according to the treatment to which 
they were randomized. 
 The Per Protocol (PP) population 
consists of all subjects in the ITT 
population with no missing visits or 
ADHD-RS-V assessments and no major 
protocol violations. Subjects will be 
analyzed according to the treatment 
they actually received. 
 The Safety Population consists of all 
subjects who receive at least one dose 
of SM. 
 
 
 PK population will include all subjects in 
the safety population who had ≤1 non-
below-the-limit-of-quantitation PK 
sample drawn. 
7.3 Analysis Populations, p.36 
 The Randomized population will include 
all enrolled subjects who had a baseline 
visit and are randomized via the IWRS. 
 The Intent-to-Treat (ITT) population for 
efficacy will include all randomized 
subjects who took at least one dose of 
study medication and had a Baseline and 
≥1 post-Baseline randomization ADHD-
RS-V5 assessment. Subjects will be 
analyzed according to the treatment to 
which they were randomized. 
 The Per Protocol (PP) population consists 
of all subjects in the ITT population who 
completed all 10 visits with no missing 
visits or ADHD-RS-V5 assessments and no 
major protocol violations. Subjects will be 
analyzed according to the treatment they 
actually received. 
 The Safety Population consists of all 
subjects randomized into the study who 
receive at least one dose of SM. Subjects 
will be analyzed according to the 
treatment they actually received.  
 The PK population will include all 
subjects in the safety population who 
had ≤ ≥ 1 non below the limit of
quantitation PK sample drawn that is not 
below the LLOQ. 
Updated for 
consistency 
with revised 
SAP 
49 
7.4 Demographics and Baseline Analysis, 
p.34 
Demographic/baseline variables include 
age, sex, ethnicity, race, height and weight 
at screening, and medical history will be 
summarized using descriptive statistics for 
continuous variables and using counts and 
percentages for categorical variables.   
7.4 Demographics and Baseline Analysis, 
p.37 
Demographic/baseline variables includeing 
age, age group, sex, ethnicity, race, height 
and weight at screening, and medical 
history BMI will be summarized using 
descriptive statistics for continuous 
variables and using counts and percentages 
for categorical variables.  
Updated for 
consistency 
with revised 
SAP 
50 
7.4 Demographics and Baseline Analysis, 
p.34 
n/a 
 
 
7.4 Demographics and Baseline Analysis, 
p.37 
(Added)  
Baseline disease characteristics will 
include ADHD-RS-5 Total score, subscale 
scores, and hyperactivity/impulsivity 
Updated for 
consistency 
with revised 
SAP 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 18 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
score. These will be summarized for the 
ITT population. 
Baseline comparability among the 
treatment groups will be summarized 
using a chi-square test for categorical 
variables and F-test for continuous 
variables. P-values will be used for 
descriptive purposes only. 
51 
7.5 Subject Disposition, p.35 
• Subjects in the randomized population 
• Subjects in the ITT population 
 
• Subjects treated (safety population) 
 
 
Within each of the previous categories, 
the number and percentage of subjects 
who completed and discontinued from 
the study and the primary reason for 
discontinuation will be summarized.  The 
reason for discontinuation may include 
any of the following: 
7.5 Subject Disposition, p.37 
• Subjects in the randomized population 
• Subjects in the ITT population 
• Subjects in the PP population 
• Subjects treated (in the safety 
population) 
 
Within each of the previous categories, the 
number and percentage of subjects who 
completed and discontinued from the 
study and the primary reason for early 
discontinuation will be summarized.  The 
reason for early discontinuation may 
include any of the following: 
Updated for 
consistency 
with revised 
SAP 
52 
7.6 Study Medication Exposure and 
Compliance, p.35 
Duration of Treatment exposure will also 
be summarized using descriptive statistics 
(n, mean, SD, median, minimum, and 
maximum). 
7.6 Study Medication Exposure and 
Compliance, p.38 
Duration of Ttreatment exposure will be 
summarized by duration category and will 
also be summarized using descriptive 
statistics (n, mean, SD, median, minimum, 
and maximum). 
Updated for 
consistency 
with revised 
SAP 
53 
7.6 Study Medication Exposure and 
Compliance, p.35 
Percent of study drug compliance is 
defined as {(number of capsules dispensed 
minus number of capsules returned) / 
(date of last dose minus date of first dose 
+ 1)}* 100%. 
7.6 Study Medication Exposure and 
Compliance, p.38 
Percent of study drug compliance is defined 
as {(number of capsules dispensed minus 
number of capsules returned) /4 × (date of 
last dose minus date of first dose + 1)}* 
100%. 
Correction 
54 
7.8.1.1 Primary analysis, p.35 
The primary endpoint is change from 
baseline in ADHD-RS-V Total Score and the 
primary analysis, based on the ITT 
population, will be performed using a 
longitudinal MMRM and a restricted 
maximum likelihood (REML) approach. 
The model will include the fixed, 
categorical effects of treatment, 
investigative site, visit, and treatment-by-
7.8.1.1 Primary analysis, p.38 
The primary endpoint is change from 
baseline in ADHD RS V Total Score and the 
primary analysis, based on the ITT 
population, will be performed using a 
longitudinal MMRM and a restricted 
maximum likelihood (REML) approach. The 
model will include the fixed, categorical 
effects of treatment, investigative site, 
visit, and treatment by visit interaction, as 
Updated for 
consistency 
with revised 
SAP 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 19 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
visit interaction, as well as the continuous, 
fixed covariates of baseline score and 
baseline score-by-visit interaction.  
An unstructured (co)variance structure 
will be used to model the within-subject 
errors. If this analysis fails to converge, the 
Compound Symmetry and Toeplitz 
structures will be tested. The covariance 
structure converging to the best fit as 
determined by Akaike’s information 
criterion will be used. The Kenward-Roger 
approximation will be used to estimate 
denominator degrees of freedom.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Each of the treatment groups (SPN-812 ER 
200 and 400 mg) will be compared with 
Placebo. The p-values, Least Squares (LS) 
of treatment means, differences between 
the LS treatment means and placebo, and 
95% confidence intervals for the 
treatment differences will be computed. 
 
 
 
 
 
well as the continuous, fixed covariates of 
baseline score and baseline score by visit 
interaction.  
An unstructured (co)variance structure will 
be used to model the within subject errors. 
If this analysis fails to converge, the 
Compound Symmetry and Toeplitz 
structures will be tested. The covariance 
structure converging to the best fit as 
determined by Akaike’s information 
criterion will be used. The Kenward Roger 
approximation will be used to estimate 
denominator degrees of freedom.  
The primary efficacy variable, change from 
baseline in ADHD-RS-5 Total Score to 
Week 8 (EOS), will be analyzed using 
MMRM, which assumes that missing data 
are MAR. The model will include fixed 
effect terms for baseline ADHD-RS-5 Total 
Score, age group, treatment, visit, and 
treatment-by-visit interaction as 
independent variables. The model 
parameters will be estimated using 
restricted maximum likelihood method 
with unstructured variance-covariance 
matrix and Kenward-Roger approximation 
to estimate denominator degrees of 
freedom. In case there is a convergence 
problem in the MMRM model with the 
unstructured variance-covariance matrix, 
the first (co)variance structure which does 
not have convergence problem will be 
used for the analysis from the following 
ordered list: 1) Toeplitz, 2) Autoregressive 
of order 1, and  3) Compound symmetry. 
The adjusted mean (LS Mean) of CFB to 
EOS for ADHD-RS-5 Total Score for each 
treatment group (Placebo, SPN-812 ER 200 
mg and SPN-812 ER 400 mg) will be 
presented, along with the corresponding 
standard error. Each of the treatment 
groups (SPN-812 ER 200 mg and 400 mg) 
will be compared with the Placebo. The p-
values, Least Squares (LS) of treatment 
means, differences between the LS 
treatment means and placebo, and 95% 
confidence intervals for the treatment 
differences will be computed. 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 20 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
To maintain the Type I error rate at 5% 
level, a sequential testing of hypotheses 
will be performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Let µ1, µ2, and µ3 be the LS Means of 
SPN-812 ER 400 mg SPN-812 ER 200 mg 
and Placebo, respectively, for CFB to EOS 
in the ADHD-RS-V Total Score. 
The first step will be to test H0:µ1 =µ3 vs. 
H1: µ1 < µ3, a comparison of the LS mean 
of SPN-812 ER 400 mg dose group and 
with the LS mean of Placebo group, at the 
5% significance level.  If H0 is not rejected, 
then formal testing stops and the 
conclusion will be that there is insufficient 
evidence to conclude that both the LS 
mean of SPN-812 ER 400 mg dose and the 
LS mean of SPN-812 ER 200 mg are less 
than the LS mean of the Placebo group.  In 
other words, neither dose group is 
efficacious. 
If H0 is rejected, then formal testing will be 
performed at step two with a test of H0: 
µ2 = µ3 vs. H1: µ2 < µ3, a comparison of 
the LS mean of SPN-812 ER 200 mg and 
with the LS mean of Placebo group at the 
5% significance level.  If the null 
hypothesis is not rejected, then formal 
testing stops and the conclusion is that 
there is only sufficient evidence to 
conclude that the LS mean of SPN-812 ER 
400 mg is less than the LS mean of the 
Placebo group.  If H0 is rejected, then it 
will be concluded that both the LS means 
To maintain the Type I error rate at 5% 
level, a sequential testing of (Westfall et al, 
1999) of the null hypotheses H01: No 
treatment mean difference between SPN-
812 ER 400 mg group and placebo group 
and H02: No treatment mean difference 
between SPN-812 ER 200 mg group and 
placebo group will be performed. If H01 is 
not rejected, then H02 will not be tested 
and the conclusion will be that neither 
dose groups are efficacious. If H01 is 
rejected, then H02 will be tested. If H02 is 
rejected then it will be concluded that 
both SPN-812 ER 400 mg and SPN-812 ER 
200 mg are superior to placebo. If H01 is 
rejected and H02 is not rejected then it will 
be concluded that only SPN-812 ER 400 mg 
is superior to placebo. 
Let µ1, µ2, and µ3 be the LS Means of SPN
812 ER 400 mg SPN 812 ER 200 mg and 
Placebo, respectively, for CFB to EOS in the 
ADHD RS V Total Score. 
The first step will be to test H0:µ1 =µ3 vs. 
H1: µ1 < µ3, a comparison of the LS mean of 
SPN 812 ER 400 mg dose group and with 
the LS mean of Placebo group, at the 5% 
significance level.  If H0 is not rejected, then 
formal testing stops and the conclusion will 
be that there is insufficient evidence to 
conclude that both the LS mean of SPN 812 
ER 400 mg dose and the LS mean of SPN
812 ER 200 mg are less than the LS mean of 
the Placebo group.  In other words, neither 
dose group is efficacious. 
If H0 is rejected, then formal testing will be 
performed at step two with a test of H0: µ2 
= µ3 vs. H1: µ2 < µ3, a comparison of the LS 
mean of SPN 812 ER 200 mg and with the 
LS mean of Placebo group at the 5% 
significance level.  If the null hypothesis is 
not rejected, then formal testing stops and 
the conclusion is that there is only 
sufficient evidence to conclude that the LS 
mean of SPN 812 ER 400 mg is less than the 
LS mean of the Placebo group.  If H0 is 
rejected, then it will be concluded that 
both the LS means of SPN 812 ER 400 mg 
and SPN 812 ER 200 mg doses are less than 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 21 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
of SPN-812 ER 400 mg and SPN-812 ER 
200 mg doses are less than the LS mean of 
the placebo group.  In other words, the 
superiority of both arms to placebo will be 
claimed. 
the LS mean of the placebo group.  In other 
words, the superiority of both arms to 
placebo will be claimed. 
55 
7.8.1.2 Sensitivity Analyses, p.36 
To confirm the results of the primary 
analysis, two sensitivity analyses will be 
performed. 
First Sensitivity Analysis - the CFB to EOS 
will be analyzed using an analysis 
covariance (ANCOVA) model with 
treatment as fixed effect and baseline 
ADHD-RS-V Total Score as a covariate 
based on the ITT population. The last 
observation carried forward (LOCF) 
method of imputation will be used for 
handling missing data. The assumption for 
using LOCF is described in Section 7.2-
Handling Missing Data. 
Second Sensitivity Analysis - The first 
sensitivity analysis will be repeated for the 
PP population. 
7.8.1.2 Sensitivity Analyses, p.39 
To confirm the results of the primary 
analysis, two sensitivity analyses will be 
performed. 
First Sensitivity Analysis  the CFB to EOS 
will be analyzed using an analysis 
covariance (ANCOVA) model with 
treatment as fixed effect and baseline 
ADHD RS V Total Score as a covariate 
based on the ITT population. The last 
observation carried forward (LOCF) method 
of imputation will be used for handling 
missing data. The assumption for using 
LOCF is described in Section 7.2 Handling 
Missing Data. 
Second Sensitivity Analysis  The first 
sensitivity analysis will be repeated for the 
PP population. 
The sensitivity analysis assumes that 
missing ADHD-RS-5 Total Scores are 
MNAR. Placebo-based multiple imputation 
will be used to fill in missing values. This 
approach may be considered “worst-case” 
sensitivity analyses as it assumes that 
after discontinuation, subjects from the 
active treatment arms would adopt the 
outcome model estimated from the 
placebo arm. The placebo-based 
imputation will be implemented as 
described in the SAP. 
LOCF method 
no longer used 
56 
7.8.2 Secondary Analyses, p.36 
n/a 
7.8.2 Secondary Efficacy Analyses, p.39 
(Added)  
The secondary analyses will be based on 
the ITT population with missing values 
imputed using multiple imputation 
assuming MAR. 
All secondary analyses will be analyzed 
using ANCOVA (except CGI which uses 
ANOVA on the absolute value of CGI-I at 
Week 8 (EOS) on the change from baseline 
at Week 8 (EOS) with treatment and 
baseline as fixed effect. Each of the 
Updated for 
consistency 
with revised 
SAP 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 22 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
treatment groups (SPN-812 ER 200 mg and 
400 mg) will be compared with the 
Placebo. The p-values, Least Squares 
means of the treatment groups, 
differences between the LS treatment 
means and placebo (SPN-812 ER 200 mg 
minus Placebo and SPN-812 ER 400 mg 
minus Placebo), and 95% confidence 
intervals for the treatment differences will 
be computed. 
57 
7.8.2.1 Key secondary efficacy analyses, 
p.36 
Key secondary analyses will include: 
a) Conners 3 - Treatment comparisons will 
be performed using ANCOVA or ANOVA 
on CFB to EOS as appropriate. 
b) 30% Responder Rate - The proportion 
of subjects with ≥30% improvement 
(decrease) from baseline to EOS in ADHD-
RS-V Total Score  will be calculated for 
each treatment group. The 2-sided 95% CI 
around the difference in proportions 
(SPN-812 ER dose minus Placebo) and the 
p-value from Pearson’s chi-squared test 
will be presented. 
c) Hyperactivity/Impulsivity and 
Inattention subscales of ADHD-RS-V – 
analyzed as for Conners 3 
7.8.2.1 Key secondary efficacy analyses, 
p.39 
Key secondary analyses will include: 
The analyses of key secondary objectives 
will be conducted on the following 
sequentially ordered endpoints for testing: 
1) CGI-I, 2) Conners 3 – Parent composite 
T-score, and 3) WFIRS-P. 
To preserve the overall type I error rate at 
0.05 for the key secondary endpoints, a 
sequential testing procedure will be used 
with the following features.  
First, only dose or doses that are 
significantly different from placebo for the 
primary endpoint will be tested for 
secondary endpoints. If the primary 
endpoint analysis does not show a 
rejection of H01 (i.e., the 400 mg is not 
superior to placebo) then no multiplicity 
adjustment will be performed for any of 
the key secondary endpoints.  If the 
primary endpoint analysis indicates that 
only 400 mg dose is superior to placebo 
(only H01 is rejected), no multiplicity 
adjustment is required. Otherwise, 
multiplicity adjustment will be performed 
as in the following. 
The first of the secondary endpoints (CGI-
I) will be used to test each treatment 
group to placebo using a sequential 
testing of the null hypotheses H01: No 
treatment mean difference between SPN-
812 ER 400 mg group and placebo group 
and H02: No treatment mean difference 
between SPN-812 ER 200 mg group and 
placebo group will be performed. If H01 is 
not rejected, then H02 will not be tested 
Updated for 
consistency 
with revised 
SAP 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 23 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
and the conclusion will be that neither 
dose groups are efficacious. If H01 is 
rejected, then H02 will be tested. If H02 is 
rejected, then it will be concluded that 
both SPN-812 ER 400 mg and SPN-812 ER 
200 mg are superior to Placebo. If H02 is 
not rejected, then it will be concluded that 
only SPN-812 ER 400 mg is superior to 
placebo. Then, the second secondary 
endpoint (Conners 3) will be tested in the 
same manner but only using those doses 
that were retained from the primary and 
the first secondary endpoint. Finally, the 
third key secondary endpoint (WFIRS-P) 
will be tested in the same manner but only 
using those doses that were retained from 
the primary, the first key secondary 
endpoint, and the second key secondary 
endpoints. 
a) CGI-I – The absolute value of CGI-I at 
EOS will be analyzed using ANCOVA with 
fixed effects for treatment and baseline as 
a covariate. To compare the treatment 
groups, the difference in LS means (SPN-
812 ER 200 mg minus Placebo and SPN-812 
ER 400 mg minus Placebo) will be 
presented along with the 95% confidence 
interval (CI) around the difference and p-
value. 
b) Conners 3 - Parent - Treatment 
comparisons will be performed using 
ANCOVA or ANOVA on CFB to EOS as 
appropriate. A composite T-score will be 
calculated by averaging over the six 
domains, and the change from baseline to 
Week 8 (EOS) in the composite T-score will 
be analyzed using ANCOVA model with 
fixed effects for treatment and baseline as 
a covariate. Each of the treatment groups 
(SPN-812 ER 200 mg and 400 mg) will be 
compared with the Placebo. The p-values, 
Least Squares means, differences between 
the LS treatment means and placebo, and 
95% confidence intervals for the 
treatment differences will be computed. 
b c) 30% Responder Rate  The proportion 
of subjects with ≥30% improvement 
(decrease) from baseline to EOS in ADHD

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 24 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
RS V Total Score  will be calculated for each 
treatment group. The 2 sided 95% CI 
around the difference in proportions (SPN
812 ER dose minus Placebo) and the p
value from Pearson’s chi squared test will 
be presented. WFIRS-P - The change from 
baseline in WFIRS-P to Week 8 (EOS) will 
be analyzed using ANCOVA model with 
fixed effects for treatment and baseline as 
a covariate. Missing Subscale scores and 
Total Score will be handled using multiple 
imputation under MAR assumption for 
inferential analyses. Each of the treatment 
groups (SPN-812 ER 200 mg and 400 mg) 
will be compared with the Placebo. The p-
values, LS means of treatment groups, 
differences between the LS means and 
placebo, and 95% confidence intervals for 
the treatment differences will be 
computed. 
c) Hyperactivity/Impulsivity and Inattention 
subscales of ADHD RS V  analyzed as for 
Conners 3 
(Added) 
To preserve the overall type I error rate at 
0.05 for the key secondary endpoints, a 
sequential testing procedure will be used 
with the following features. First, only 
dose or doses that are significantly 
different from placebo for the primary 
endpoint will be tested for secondary 
endpoints. If the primary endpoint 
analysis indicates that only one dose (400 
mg) is significant, no multiplicity 
adjustment is required. Otherwise, 
multiplicity adjustment will be performed 
as in the following. 
The first of the secondary endpoints (CGI-
I) will be used to test each treatment 
group to placebo using a sequential 
testing of the null hypotheses H01: No 
treatment mean difference between SPN-
812 ER 400 mg group and placebo group 
and H02: No treatment mean difference 
between SPN-812 ER 200 mg group and 
placebo group will be performed. If H01 is 
not rejected, then H02 will not be tested 
and the conclusion will be that neither 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 25 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
dose groups are efficacious. If H01 is 
rejected, then H02 will be tested. If H02 is 
rejected, then it will be concluded that 
both SPN-812 ER 400 mg and SPN-812 ER 
200 mg are superior to Placebo. If H02 is 
not rejected, then it will be concluded that 
only SPN-812 ER 400 mg is superior to 
placebo. Then, the second secondary 
endpoint (Conners 3) will be tested in the 
same manner but only using those doses 
that were retained from the primary and 
the first secondary endpoint. Finally, the 
third key secondary endpoint (WFIRS-P) 
will be tested in the same manner but only 
using those doses that were retained from 
the primary, the first key secondary 
endpoint, and the second key secondary 
endpoints. 
58 
7.8.2.2 Additional secondary analyses, 
p.37 
Additional secondary analyses include 
treatment comparisons using ANCOVA or 
ANOVA, on CFB to EOS as appropriate for 
the following: 
a) WFIRS-P  
b) PSI-4-SF 
c) CGI-S/I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.8.2.2 Additional secondary analyses, p.40 
Additional secondary analyses of the 
secondary efficacy variables will include: 
treatment comparisons using ANCOVA or 
ANOVA on CFB to EOS, as appropriate for 
the following: 
a) WFIRS P 50% Responder rate for ADHD-
RS-5 - Percent reduction will be calculated 
as: % reduction = 100*(ADHD-RS-5 Total 
Score at Week 8 (EOS) - Baseline ADHD-RS-
5 Total Score)/Baseline ADHD-RS-5 Total 
Score. The proportion of responders will 
be presented for each treatment group. 
The 2-sided 95% CI around the difference 
in proportions (SPN-812 ER 200 mg minus 
Placebo, SPN-812 ER 400 mg minus 
Placebo) and the p-value from Pearson’s 
Chi-squared Test or Fisher’s Exact Test  will 
be presented. 
b) PSI-4-SF - The change from baseline in 
PSI-4 total score to Week 8 (EOS) will be 
analyzed using ANCOVA model with fixed 
effects for treatment and baseline as a 
covariate. Each of the treatment groups 
(SPN-812 ER 200 mg and 400 mg) will be 
compared with the Placebo. The p-values, 
LS means of treatment groups, differences 
between the LS means and placebo will be 
presented. 
Updated for 
consistency 
with revised 
SAP 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 26 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
 
 
 
 
 
 
 
 
 
The secondary analyses will be repeated 
for the per protocol population. 
c) CGI S/I ADHD-RS-5 Inattention and 
Hyperactivity/Impulsivity subscales - The 
primary analysis for ADHD-RS-5 Total 
score will be repeated for the change from 
baseline to EOS in ADHD-RS-5 Inattention 
and the change from baseline to Week 8 
(EOS) in Hyperactivity/Impulsivity 
subscales. 
d) Conners 3 - Self – The analysis for 
Conners 3 - Parent will be repeated for self 
scores. 
The key secondary analyses will be 
repeated for the per protocol population 
for supplementary analyses. 
59 
Version 4.0, (Added) 7.8.3 Subgroup Analyses, p.41 
The primary and key secondary efficacy variable analyses may be repeated by the 
following subgroups to explore the heterogeneity of treatment effect: 
a) Gender (male, female) 
b) Age (6-9 years, 10-11 years) 
c) Race (white, non-white) 
Updated for 
consistency 
with revised 
SAP 
60 
Version 4.0 (Added) 7.8.4 Exploratory Analyses, p.41 
 
 
 
 
 
 
 
Updated for 
consistency 
with revised 
SAP 
61 
7.11 Pharmacokinetic Analyses, p.37 
n/a 
 
 
 
 
 
   
 
The structural model for viloxazine may 
include data from studies in which 
sampling was more intensive than in the 
present study.   
7.11 Pharmacokinetic Analyses, p.41 
(Added) Plasma concentrations for 
viloxazine (and 5-hydroxy-viloxazine 
glucuronide, if applicable) will be 
provided. 
 
 
   
 
The structural model for viloxazine (and 5-
hydroxy-viloxazine glucuronide, if 
applicable) may include data from studies 
in which sampling was more intensive than 
in the present study.   
Assessment of 
viloxazine 
metabolite 
 
 
 

Supernus Pharmaceuticals, Inc. 
CONFIDENTIAL 
17 Sep 2018 
Protocol 812P303 
 
Page 27 of 27 
 
This document is confidential.  It contains proprietary information of Supernus® Pharmaceuticals, Inc.  Any viewing or disclosure 
of such information that is not authorized in writing by the Sponsor is strictly prohibited.  Such information may be used solely 
for the purpose of reviewing or performing this study. 
 
# 
812P303 Protocol Version 3.0 
dated 07 September 2017 
812P303 Protocol Version 4.0 
dated 17 September 2018 
Rationale 
62 
7.11 Pharmacokinetic Analyses, p.37 
n/a 
7.11 Pharmacokinetic Analyses, p.41 
(Added) Population PK analyses will be 
reported separately from the clinical study 
report. 
Clarification 
63 
7.12 Pharmacogenomic Analysis, p.37 
Individual data will be presented as a 
listing and summaries will be tabulated 
using descriptive statistics. 
7.12 Pharmacogenomic Analysis, p.41 
If PGx testing is performed, Iindividual data 
will be presented as a listing and 
summaries will be tabulated using 
descriptive statistics. 
Clarification 
64 
7.13 Safety Analysis, p.37 
Verbatim description and all Medical 
Dictionary for Regulatory Activities 
(MedDRA) level terms, including the 
Lower Level Terms, for all AEs will be 
contained in the subject data listings. 
 
For quantitative laboratory parameters, 
both actual values and change from Visit 2 
values will be summarized. 
 
Both actual values and change from Visit 2 
to Visit 10 will be summarized. 
7.13 Safety Analysis, p.42 
Verbatim description and all Medical 
Dictionary for Regulatory Activities 
(MedDRA) SOCs and PTs level terms, 
including the Lower Level Terms, for all AEs 
will be contained in the subject data 
listings. 
For quantitative laboratory parameters, 
both actual values and change from Visit 2  
Screening values will be summarized. 
 
Both actual values and change from Visit 2 
to Visit 10 baseline will be summarized. 
Clarification 
65 
8.3.4 Bioanalytical Sample Handling, p.39 
Viloxazine concentrations in plasma 
samples will be determined using a 
validated chromatographic method.   
8.3.4 Bioanalytical Sample Handling, p.43 
Viloxazine and 5-hydroxy-viloxazine 
glucuronide concentrations in plasma 
samples will be determined using a 
validated chromatographic method.   
(Added) Viloxazine concentrations will be 
reported as viloxazine free base.  
Assessment of 
viloxazine 
metabolite 
66 
10 References, p.42 
Gajria K, Kivote V, Sikirica V, Reilly K, 
Kosinski M, Erder MH. Validation of the 
Weiss Functional Impairment Rating Scale 
– Parent Report Form in attention 
deficit/hyperactivity disorder. European 
Neuropsychopharmacology, Volume 24, 
S711 - S712. 
10 References, p.46 
Gajria K, Kivote V, Sikirica V, Reilly K, 
Kosinski M, Erder MH. (2015) Validation of 
the Weiss Functional Impairment Rating 
Scale – Parent Report Form in attention 
deficit/hyperactivity disorder. European 
Neuropsychopharmacology, Volume 24, 
S711 - S712. 
(Added) Westfall, Peter H., Tobias, Randall 
D., and Wolfinger, Russell D., (1999). 
Multiple Comparisons and Multiples Tests 
Using SAS®, Cary, NC: SAS Institute Inc. 
Editorial 
change